US20110312087A1 - Bioreactor for the cultivation of mammalian cells - Google Patents

Bioreactor for the cultivation of mammalian cells Download PDF

Info

Publication number
US20110312087A1
US20110312087A1 US13/148,503 US201013148503A US2011312087A1 US 20110312087 A1 US20110312087 A1 US 20110312087A1 US 201013148503 A US201013148503 A US 201013148503A US 2011312087 A1 US2011312087 A1 US 2011312087A1
Authority
US
United States
Prior art keywords
bioreactor
impeller
volume
sparger
tank
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/148,503
Other languages
English (en)
Inventor
Mohsan Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Biologics PLC
Original Assignee
Lonza Biologics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics PLC filed Critical Lonza Biologics PLC
Assigned to LONZA BIOLOGICS PLC reassignment LONZA BIOLOGICS PLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KHAN, Mohsan
Publication of US20110312087A1 publication Critical patent/US20110312087A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/02—Tissue, human, animal or plant cell, or virus culture apparatus with means providing suspensions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/58—Reaction vessels connected in series or in parallel
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/04—Apparatus for enzymology or microbiology with gas introduction means
    • C12M1/06—Apparatus for enzymology or microbiology with gas introduction means with agitator, e.g. impeller
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
    • C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/02—Stirrer or mobile mixing elements
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/02—Stirrer or mobile mixing elements
    • C12M27/08—Stirrer or mobile mixing elements with different stirrer shapes in one shaft or axis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/18—Flow directing inserts
    • C12M27/20—Baffles; Ribs; Ribbons; Auger vanes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/06—Nozzles; Sprayers; Spargers; Diffusers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration

Definitions

  • the present invention relates to bioreactors and methods for the large scale cultivation of mammalian cells using these bioreactors.
  • One of the objects of the present invention is to provide bioreactors and methods, which allow the cultivation of mammalian cells in large scale volumes. Furthermore, it is an object of the present invention to provide bioreactors and methods, which allow the cultivation of mammalian cells under optimal conditions, even if grown in large scale volumes and therefore allow a process performance and product quality independent of the size of the bioreactor.
  • process parameters such as pH, dissolved oxygen tension (DOT) and temperature
  • the present invention solves the technical problems underlying the present invention by the provision of bioreactors, bioreactor systems and methods for the cultivation of eukaryotic cells, especially of mammalian cells, according to the claims.
  • the present invention solves the technical problem underlying the present invention especially by the provision of a bioreactor for the cultivation of mammalian cells, characterised in that said bioreactor has at least two impellers. Furthermore, the present invention solves the technical problem underlying the present invention by the provision of a method for the cultivation and propagation of mammalian cells characterised in that at least one mammalian cell is cultivated under suitable conditions and in a suitable culture medium in a bioreactor, which has at least two impellers.
  • the present invention solves the technical problems underlying the present invention by the provision of a bioreactor system for the cultivation of mammalian cells characterised in that a) a first bioreactor with a volume of at least 500 l is connected with b) a second bioreactor with a volume of at least 2000 l, which has a volume greater than the first bioreactor and wherein the second bioreactor with a volume of at least 2000 l is connected with c) a third bioreactor having at least two impellers and a volume of at least 10 000 l, which has a volume greater than the second bioreactor.
  • the present invention solves the technical problem underlying the present invention furthermore by the provision of a method to cultivate and propagate mammalian cells, characterised in that a) at least one mammalian cell is cultivated under suitable conditions and in a suitable culture medium in a first bioreactor with a volume of at least 500 l, b) the medium containing the cells obtained by propagation of the at least one mammalian cell is transferred into a second bioreactor with a volume of at least 2000 l, c) the transferred cells are cultivated in the second bioreactor with a volume of at least 2000 l, d) the medium containing the cells obtained in step c) is transferred into a third bioreactor with a volume of at least 10 000 l and e) the transferred cells are cultivated in the third bioreactor with a volume of at least 10 000 l.
  • the cultivated cells are eukaryotic cells, preferably animal cells, more preferably mammalian cells.
  • the mammalian cells can be for example human cell lines, mouse myeloma (NS0)-cell lines, Chinese hamster ovary (CHO)-cell lines or hybridoma-cell lines.
  • the mammalian cells are CHO-cell lines.
  • the cultivated cells are used to produce antibodies, more preferably monoclonal antibodies, and/or recombinant proteins, more preferably recombinant proteins for therapeutic use.
  • the cells may produce peptides, amino acids, fatty acids or other useful biochemical intermediates or metabolites.
  • the target concentration of the proteins produced by the cultivated cells is more than 0.5 g/l, preferably more than 2.0 g/l and most preferred more than 10.0 g/l.
  • the method according to the invention can be used as a batch or in a fed-batch process.
  • the cell-culture-medium used in the method according to the invention is preferably protein free medium, the design does not exclude the use of protein containing streams.
  • a bioreactor is a biocompatible tank or vessel having additional equipment, for example impellers, baffles, spargers and/or ports, which specifically allows for the cultivation and propagation of mammalian cells.
  • the tank or vessel is in the form of a tube, having on both ends of the tube, which build preferably the top and the bottom of the tank, plates.
  • the plates are called head plate and base plate.
  • the base plate is an American Society of Mechanical Engineers Flanged and Dished (ASME F&D) designed base plate.
  • the head-plate design preferably accommodates a manway or is preferably a flanged head plate to allow access/removal of the impellers.
  • the total tank height is the tangential line from the inner tank side of the base to the inner tank side of the head of the tank.
  • the freeboard height is defined as the length of straight side above the liquid head when the bioreactor is filled to it's operating volume.
  • a minimum freeboard height is necessary taking into account the extent of foam build up during operation, gas hold up at maximum allowed agitation and aeration and errors in metering liquid.
  • the bioreactor according to the invention has a volume of preferably at least 500 l, more preferably of at least 1000 l, more preferably of at least 4000 l, even more preferably of at least 10 000 l, even more preferably of at least 20 000 l. Most preferably the bioreactor according to the invention has a volume of 1000 l, 1307 l, 4000 l, 5398 l, 20 000 l or 27 934 l.
  • the bioreactor has a maximum volume of 100 000 l, more preferably the bioreactor has a maximum volume of 50 000 l, most preferably the bioreactor has a maximum volume of 30 000 l.
  • the design of the bioreactors according to the present invention ensures a homogenous environment with respect to process parameters such as pH, dissolved oxygen tension (DOT) and temperature, maintaining a well mixed cell suspension and blending nutrient feeds within the bioreactor. This provides the necessary physicochemical environment for optimal cell growth, product accumulation and product quality.
  • the design of the bioreactors according to the present invention furthermore ensures the maintenance of geometric similarity. This allows a scale down model to be developed at 12 litre laboratory and 500 litre pilot scales.
  • the bioreactor for the cultivation of mammalian cells according to the invention has at least two impellers. More preferably, the bioreactor has two impellers, even more preferably a top impeller and a bottom impeller.
  • the bioreactor for the cultivation of mammalian cells according to the invention has preferably at least one top impeller and at least one bottom impeller, wherein the top impeller is preferably a hydrofoil impeller.
  • the bioreactor for the cultivation of mammalian cells according to the invention has preferably at least one top impeller and at least one bottom impeller, wherein the top impeller is a hydrofoil impeller.
  • the bioreactor for the cultivation of mammalian cells according to the invention has preferably a volume of at least 1000 l and at least one top impeller and at least one bottom impeller, wherein the top impeller is a hydrofoil impeller.
  • the bioreactor for the cultivation of mammalian cells according to the invention has preferably a volume of at least 4000 l and at least one top impeller and at least one bottom impeller, wherein the top impeller is preferably a hydrofoil impeller.
  • the bioreactor for the cultivation of mammalian cells according to the invention has preferably a volume of at least 4000 l and at least one top impeller and at least one bottom impeller, wherein the top impeller is a hydrofoil impeller.
  • the top impeller is a hydrofoil impeller.
  • the top impeller can be used preferably to provide strong bulk mixing.
  • the bottom impeller is a hydrofoil impeller.
  • the top impeller and the bottom impeller are a hydrofoil impeller.
  • At least the top impeller is a hydrofoil impeller. In a preferred embodiment of the invention all impellers are hydrofoil impellers.
  • the bottom impeller is a high-solidity pitch-blade impeller or a high-solidity hydrofoil impeller.
  • the bottom impeller can be used preferably for the dissipation of sparged gas.
  • the hydrofoil impellers provide much greater liquid motion, resulting in a greater bulk-mixing, for a given amount of power input. This can also depend of the flow number (N q ).
  • non-hydrofoil impellers can provide liquid motion but at greater power inputs. This can have consequences on the health of shear-sensitive mammalian cells.
  • the hydrofoil impeller is a down-flowing impeller or a up-flowing impeller.
  • the top impeller is a down-flowing impeller. In a preferred embodiment of the invention the top impeller is a down-flowing axial hydrofoil impeller.
  • the pulling down characteristics of the top impeller are used to mix the well aerated liquid surface with the liquid bulk.
  • the hydrofoil impeller is a high efficiency hydrofoil impeller.
  • the hydrofoil impeller is a Chemineer—model SC-3 impeller, a LIGHTNIN—model A310 or A510 impeller, a Promix—model PHF series impeller or a Cleaveland Eastern Mixers impeller.
  • the top impeller is a high efficiency hydrofoil impeller.
  • the top impeller is a Chemineer—model SC-3 impeller, a LIGHTNIN—model A310 or A510 impeller, a Promix—model PHF series impeller or a Cleaveland Eastern Mixers impeller.
  • the top impeller is preferably a three-bladed hydrofoil design impeller, for example a A310-type impeller from LIGHTNIN.
  • the bottom impeller is preferably a four-pitched-bladed high-solidity impeller, for example of the A315-type from LIGHTNIN.
  • the impeller to tank diameter ratio of the top impeller (D top /T) and/or of the bottom impeller (D bottom /T) is preferably at least 0.35 and at most 0.55, more preferably at least 0.40 and at most 0.48, and most preferably at least 0.44, and at most 0.46.
  • a diameter greater than 0.5 results in disruption in axial flow, hence poor agitation and aeration.
  • the top impeller power number (N p ) is preferably at least 0.1 and at most 0.9, more preferably at least 0.25 and at most 0.35, most preferably 0.3.
  • the top impeller flow number (N q ) is preferably at least 0.4 and at most 0.9, more preferably at least 0.50 and at most 0.60, most preferably 0.56.
  • the bottom impeller power number (N p ) is preferably at least 0.5 and at most 0.9, more preferably at least 0.70 and at most 0.80, most preferably 0.75.
  • the bottom impeller flow number (N q ) is preferably at least 0.50 and at most 0.85, more preferably at least 0.70 and at most 0.80, most preferably 0.73.
  • the impeller power number (N p ) is a measure of an impeller efficiency to impart the kinetic energy of the rotating impeller blades to the fluid. It is important in quantifying the gas dispersion.
  • the impeller flow number (N q ) is a measure of pumping ability of the impeller and is important in quantifying fluid bulk movement.
  • the agitation rate of the at least two impellers is dependent on the scale. However, in a particularly preferred embodiment of the invention the agitation rate of the at least two impellers is at most 200 rounds per minute (rpm), more preferably at most 165 rpm.
  • the impeller spacing (D s ) is the space between the at least two impellers. It is in a particularly preferred embodiment of the invention at least 1 ⁇ the diameter of the bottom impeller (D bottom ) and at most 2 ⁇ D bottom , more preferably it is 1.229 ⁇ D bottom or 2 ⁇ D bottom . This will allow both impellers to remain submerged at the lowest post-inoculation volume.
  • the liquid height above the upper impeller (D o ) is in a particularly preferred embodiment of the invention at least 0.3 ⁇ the diameter of the top impeller (D top ) and at most 2.5 ⁇ D top . More preferably it is at least 0.5 ⁇ D top and at most 2.0 ⁇ D top .
  • the bottom clearance (D c ) is the clearance between the tank bottom and the centre-line of the bottom impeller. In a particularly preferred embodiment of the invention it is at least 0.35 ⁇ D bottom , more preferably it is either 0.4 ⁇ D bottom or 0.75 ⁇ D bottom .
  • the design of the impellers in the bioreactor according to the present invention provides optimal hydrodynamic characteristics in terms of bulk mixing, gas dispersion and low shear.
  • the mammalian cells are kept in a homogeneous suspension by agitation via the impeller system according to the present invention.
  • the design of the impellers in the bioreactor according to the present invention provides rapid mixing, maintain homogeneity, maintain mammalian cells in suspension and gas bubble dispersion.
  • the design of the impellers in the bioreactor according to the present invention minimises cell damage through shear forces originating from impeller geometry and eddies or vortices created behind the impeller blades.
  • the at least two impellers are a top driven agitator system.
  • the supply of air, especially compressed air, or specific gases, preferably oxygen, nitrogen and/or CO 2 is realised preferably through at least one sparger.
  • the bioreactor according to the invention has preferably at least one sparger, more preferably the bioreactor has one sparger or two spargers.
  • the bioreactor according to the invention has preferably two spargers.
  • the bioreactor has at least one sparger with a pipe-geometry.
  • the at least one sparger is of the flute-type or is a sintered sparger.
  • the at least one sparger is of the flute-type.
  • a crescent pipe is explored.
  • the curvature of the crescent is preferably 0.8 ⁇ D bottom .
  • the crescent circumference is preferably 240° of the complete circumference of 0.8 ⁇ D bottom ring.
  • the at least one sparger provides sufficient oxygen mass transfer (characterised by K L a) to meet the oxygen demand of the culture.
  • the at least one sparger provides a K L a up to 20 h ⁇ 1 for cultures reaching up to 20 ⁇ 10 6 cells per ml with an oxygen uptake rate of 5 mmol/l per hour.
  • Two spargers used as a dual sparger system allow the removal of dissolved CO 2 and control of dissolved oxygen tension (DOT). Fluted spargers offer the benefits of easier cleaning in place (CIP) and sterilisation in place (SIP), aids with dCO 2 stripping and reduced operational costs as it is multiple use.
  • Sintered spargers provide higher K L a values.
  • the lower intrinsic K L a value with the fluted sparge design can be compensated by the use of oxygen enriched air.
  • the gas flow rates are scaled up on the basis of constant superficial gas velocity.
  • interfacial shear occurs as sparged gas bubbles coalesce and burst [ref: Ma N, Koelling K W, Chalmers J J. Biotechnol Bioeng. 2002 Nov. 20; 80(4):428-37. Erratum in: Biotechnol Bioeng. 2003 Feb. 5; 81(3):379].
  • the interfacial shear can be minimised through a combination of approaches first by promoting surface aeration through good mixing of the liquid surface with the liquid bulk and secondly higher oxygen driving force by segregated oxygenation of cultures through the preferably two spargers.
  • the prescribed positioning of the hydrofoil impeller, particularly the liquid height above the upper impeller, D O preferably being around 0.5 ⁇ D top , below the liquid surface can aid strong and continuous exchange of the liquid surface with the liquid bulk thereby mixing the well oxygenated liquid surface with less oxygenated liquid bulk.
  • the segregation of the ‘on-demand’ oxygenated sparged gas through the control sparger from the non-oxygenated sparged gases (such as CO 2 , air and nitrogen ballasts) through a ballast sparger can allow greater residence time and path length of highly oxygenated sparge gas bubbles in the fluid bulk before disengaging out of the fluid bulk and into the headspace. This can permit greater oxygen transfer rates to be provided for a given volumetric mass transfer coefficient, k La .
  • the residence time and path length of the sparged gas bubbles can be extended further through specifying down-flowing axial hydrofoil impellers that continuingly pull the liquid surface and liquid bulk down.
  • the bioreactor according to the invention has preferably at least one baffle, more preferably at least two baffles.
  • the bioreactor according to the invention has most preferably four baffles.
  • Baffles are vertical radially located plates. Baffles are used to prevent the formation of a funnel or vortex formation.
  • the length of the at least one baffle is 1.1 ⁇ the total straight height (H) of the bioreactor.
  • the width of the baffle (W) is preferably 0.1 ⁇ the internal diameter of the tank (T).
  • the baffle clearance (W c ) is preferably 0.01 ⁇ the internal diameter of the tank (T).
  • the thickness of the at least one baffle is not specified but the thickness needs to ensure rigidity to the radial component of the fluid flow. Additionally thickness needs to ensure the baffle plates are not warped during SIP thereby affecting the baffle to tank wall clearance.
  • the bioreactor according to the invention has preferably at least two ports for alkali addition. More preferably, the bioreactor has two ports for alkali addition. Most preferably, the bioreactor has two ports for alkali addition, wherein the first port is located at the central line of the bottom impeller and the second port is located at the central line of the top impeller. Preferably the pH probes are located diametrically opposite the alkali addition points into the bioreactor.
  • the bioreactor has a volume of 1000 l.
  • the head volume (V h ) of a 1000 l bioreactor is preferably at least 45 l and at most 65 l, more preferably the head volume is 55 l.
  • the base volume (V b ) of the 1000 l bioreactor is preferably at least 45 l and at most 65 l, more preferably the base volume is 55 l.
  • the tank internal diameter (T) of the 1000 l bioreactor according to the invention is preferably at least 850 mm and at most 900 mm, more preferably the tank internal diameter is 864 mm.
  • the tank cross-sectional area (A) of the 1000 l bioreactor according to the invention is preferably at least 0.55 m 2 and at most 0.65 m 2 , more preferably the tank cross-sectional area is 0.586 m 2 .
  • the head height (H h ), which is the height of the head-plate, and/or the base height (H b ), which is the height of the base-plate, of the bioreactor with a volume of 1000 l according to the invention is preferably at least 120 mm and at most 180 mm, more preferably the head height and/or the base height is 151 mm.
  • the total tank height of the 1000 l bioreactor according to the invention is preferably at least 2000 mm and at most 2600 mm, more preferably the total tank height is 2347 mm.
  • the top impeller diameter (D top ) and/or the bottom impeller diameter (D bottom ) of the 1000 l bioreactor according to the invention is preferably at least 350 mm and at most 400 mm, more preferably the top impeller diameter and/or the bottom impeller diameter is 381 mm.
  • the clearance between the tank bottom and centre-line of the bottom impeller (D c ) is for the 1000 l bioreactor according to the invention, preferably at least 120 mm and at most 180 mm, more preferably the clearance is 152 mm.
  • the distance between the at least two impellers is for the 1000 l bioreactor, according to the invention, preferably at least 730 and at most 790 mm, more preferably the impeller separation is 762 mm.
  • the impeller shaft diameter for the 1000 l bioreactor according to the invention is preferably at least 102 mm and at most 152 mm. If the 1000 l bioreactor according to the invention has baffles, the length of the baffles is preferably at least 2000 mm and at most 2400 mm, more preferably the length is 2250 mm.
  • the width of the baffles for the 1000 l bioreactor according to the invention is preferably at least 70 mm and at most 100 mm, more preferably the width is 86 mm.
  • the baffle clearance for the 1000 l bioreactor according to the invention is preferably at least 7 mm and at most 11 mm, more preferably the baffle clearance is 9 mm.
  • the baffle height (H baffle ) for the 1000 l bioreactor according to the invention is preferably at least 2000 mm and at most 2200 mm, more preferably the baffle height is 2099 mm.
  • the 1000 l bioreactor according to the invention has preferably at least one sparger, more preferably it has one sparger.
  • the at least one sparger of the 1000 l bioreactor according to the invention has preferably an orifice- or pore-size of at least 1.5 mm and at most 2.5 mm, more preferably the orifice- or pore-size is 2 mm.
  • the orifice- or pore-number is preferably at least 20 and at most 40, more preferably the orifice- or pore-number is 30.
  • the sparger length (S L is preferably at least 150 mm and at most 550 mm, more preferably the sparger length is 305 mm.
  • the sparger to tank bottom clearance (S c ) of the 1000 l bioreactor according to the invention is preferably at least 50 mm and at most 75 mm, more preferably the sparger to tank bottom clearance is 64 mm.
  • the sparger to bottom impeller clearance (D c ⁇ S c ) of the 1000 l bioreactor according to the invention is preferably at least 75 mm and at most 100 mm, more preferably the sparger to bottom impeller clearance is 88 mm.
  • the bioreactor has a volume of 4000 l.
  • the head volume (V h ) of a 4000 l bioreactor is preferably at least 340 l and at most 370 l, more preferably the head volume is 359 l.
  • the base volume (V b ) of the 4000 l bioreactor is preferably at least 340 l and at most 370 l, more preferably the base volume is 359 l.
  • the tank internal diameter (T) of the 4000 l bioreactor according to the invention is preferably at least 1600 mm and at most 1650 mm, more preferably the tank internal diameter is 1626 mm.
  • the tank cross-sectional area (A) of the 4000 l bioreactor according to the invention is preferably at least 1.90 m 2 and at most 2.30 m 2 , more preferably the tank cross-sectional area is 2.076 m 2 .
  • the head height (H h ) and/or the base height (H b ) of the bioreactor with a volume of 4000 l according to the invention is preferably at least 260 mm and at most 300 mm, more preferably the head height and/or the base height is 282 mm.
  • the total tank height of the 4000 l bioreactor according to the invention is preferably at least 2300 mm and at most 3100 mm, more preferably the total tank height is 2817 mm.
  • the top impeller diameter (D top ) and/or the bottom impeller diameter (D bottom ) of the 4000 l bioreactor according to the invention is preferably at least 680 mm and at most 740 mm, more preferably the top impeller diameter and/or the bottom impeller diameter is 710 mm.
  • the clearance between the tank bottom and centre line of the bottom impeller (D c ) is for the 4000 l bioreactor according to the invention, preferably at least 500 mm and at most 560 mm, more preferably the clearance is 531 mm.
  • the distance between the at least two impellers is for the 4000 l bioreactor, according to the invention, preferably at least 840 mm and at most 900 mm, more preferably the impeller separation is 872 mm.
  • the impeller shaft diameter for the 4000 l bioreactor according to the invention is preferably at least 51 mm and at most 64 mm. If the 4000 l bioreactor according to the invention has baffles, the length of the baffles is preferably at least 2200 mm and at most 2600 mm, more preferably the length is 2477 mm.
  • the width of the baffles for the 4000 l bioreactor according to the invention is preferably at least 150 mm and at most 180 mm, more preferably the width is 163 mm.
  • the baffle clearance is for the 4000 l bioreactor according to the invention preferably at least 12 mm and at most 20 mm, more preferably the baffle clearance is 16 mm.
  • the baffle height (H baffle ) for the 4000 l bioreactor according to the invention is preferably at least 2100 mm and at most 2300 mm, more preferably the baffle height is 2195 mm.
  • the 4000 l bioreactor according to the invention has preferably at least one sparger, more preferably it has one sparger.
  • the at least one sparger of the 4000 l bioreactor according to the invention has preferably an orifice- or pore-size of at least 1.5 mm and at most 2.5 mm, more preferably the orifice- or pore-size is 2 mm.
  • the orifice- or pore-number for the 4000 l bioreactor according to the invention is preferably at least 80 and at most 120, more preferably the orifice- or pore-number is 100.
  • the sparger length (S L ) is preferably at least 250 mm and at most 800 mm, more preferably the sparger length is 568 mm.
  • the sparger to tank bottom clearance (S c ) of the 4000 l bioreactor according to the invention is preferably at least 315 mm and at most 360 mm, more preferably the sparger to tank bottom clearance is 337 mm.
  • the sparger to bottom impeller clearance (D c ⁇ S c ) of the 1000 l bioreactor according to the invention is preferably at least 180 mm and at most 205 mm, more preferably the sparger to bottom impeller clearance is 194 mm.
  • the bioreactor has a volume of 20 000 l.
  • the head volume (V h ) of a 20 000 l bioreactor is preferably at least 1600 l and at most 2000 l, more preferably the head volume is 1803 l.
  • the base volume (V b ) of the 20 000 l bioreactor is preferably at least 1600 l and at most 2000 l, more preferably the base volume is 1803 l.
  • the tank internal diameter (T) of the 20 000 l bioreactor according to the invention is preferably at least 2500 mm and at most 3000 mm, more preferably the tank internal diameter is 2794 mm.
  • the tank cross-sectional area (A) of the 20 000 l bioreactor according to the invention is preferably at least 5.8 m 2 and at most 6.5 m 2 , more preferably the tank cross-sectional area is 6.131 m 2 .
  • the head height (H h ) and/or the base height (H b ) of the bioreactor with a volume of 20 000 l according to the invention is preferably at least 460 mm and at most 500 mm, more preferably the head height and/or the base height is 485 mm.
  • the total tank height of the 20 000 l bioreactor according to the invention is preferably at least 4800 mm and at most 5100 mm, more preferably the total tank height is 4933 mm.
  • the top impeller diameter (D top ) and/or the bottom impeller diameter (D bottom ) of the 20 000 l bioreactor according to the invention is preferably at least 1100 mm and at most 1300 mm, more preferably the top impeller diameter and/or the bottom impeller diameter is 1219 mm.
  • the clearance between the tank bottom and centre line of the bottom impeller (D c ) is for the 20 000 l bioreactor according to the invention, preferably at least 890 mm and at most 945 mm, more preferably the clearance is 913 mm.
  • the distance between the at least two impellers is for the 20 000 l bioreactor, according to the invention, preferably at least 1200 mm and at most 1700 mm, more preferably the impeller separation is 1498 mm.
  • the impeller shaft diameter for the 20 000 l bioreactor according to the invention is preferably at least 51 mm and at most 64 mm. If the 20 000 l bioreactor according to the invention has baffles, the length of the baffles is preferably at least 4000 mm and at most 4600 mm, more preferably the length is 4365 mm.
  • the width of the baffles for the 20 000 l bioreactor, according to the invention is preferably at least 260 mm and at most 290 mm, more preferably the width is 279 mm.
  • the baffle clearance for the 20 000 l bioreactor, according to the invention is preferably at least 20 mm and at most 35 mm, more preferably the baffle clearance is 28 mm.
  • the baffle height (H baffle ) for the 20 000 l bioreactor according to the invention is preferably at least 3600 mm and at most 4050 mm, more preferably the baffle height is 3882 mm.
  • the 20 000 l bioreactor according to the invention has preferably at least one sparger, more preferably it has two spargers.
  • the 20 000 l bioreactor according to the invention has two spargers one is preferably a control sparger and one is preferably a ballast sparger.
  • the control sparger for the 20 000 l bioreactor according to the invention has preferably an orifice- or pore-size of at least 3 mm and at most 5 mm, more preferably the orifice- or pore-size is 4 mm.
  • the ballast sparger for the 20 000 l bioreactor according to the invention has preferably an orifice- or pore-size of at least 5 mm and at most 7 mm, more preferably the orifice- or pore-size is 6 mm.
  • the orifice/pore number of the control sparger for the 20 000 l bioreactor according to the invention is preferably at least 230 and at most 270, more preferably the orifice- or pore-number is 250.
  • the orifice-pore-number of the ballast sparger for the 20 000 l bioreactor according to the invention is preferably at least 85 and at most 115, more preferably the orifice- or pore-number is 100.
  • the sparger length (S L ) for the control and/or the ballast sparger is preferably at least 500 mm and at most 2000 mm, more preferably the sparger length is 1077 mm.
  • the sparger to tank bottom clearance (S c ) of the 20 000 l bioreactor according to the invention is preferably for the control and/or the ballast sparger at least 560 mm and at most 620 mm, more preferably the sparger to tank bottom clearance is 593 mm.
  • the sparger to bottom impeller clearance (D c ⁇ S c ) of the 20 000 l bioreactor according to the invention is for the control and/or the ballast sparger preferably at least 300 mm and at most 340 mm, more preferably the sparger to bottom impeller clearance is 320 mm.
  • the requirement to add ballast from a separate sparger, the ballast sparger prevents dilution of oxygen or oxygen enriched DOT demand gas with the ballast gas.
  • ballast sparger allows spargers to be located at different positions to avoid impacting DOT control on delivering desired ballast for pCO 2 control.
  • the ballast sparger can be independently designed from the control sparger.
  • the subculture ratios performed are subculture ratios of at least 1 in 5 (20% v/v) and at most 1 in 9 (11% v/v), more preferred 1 in 5 (20% v/v) or 1 in 9 (11% v/v).
  • the invention also includes a method to cultivate and propagate mammalian cells, characterised in that at least one mammalian cell is cultivated under suitable conditions and in a suitable culture medium in a bioreactor according the invention.
  • Bioreactors according to the invention include all bioreactors having at least two impellers and showing at least one feature or a combination of different features outlined above.
  • the agitation rate of the at least two impellers of the bioreactor is preferably at least 55 W/m 3 and at most 85 W/m 3 .
  • air is sparged into the culture medium with a speed of at least 5 ⁇ 10 ⁇ 5 m/s, more preferably of at least 10 ⁇ 10 ⁇ 5 m/s.
  • alkali is added through two addition ports to distribute the alkali, which are, preferably spatially separated from each other. This ensures quicker blending of alkali in the event of long re-circulation time in the tank.
  • CO 2 is preferably added via a control sparger.
  • Alkali and/or CO 2 are preferably used to regulate the pH of the culture-medium.
  • control and back-up probes be in the lower port ring at 913 mm from tank bottom.
  • the method according to the invention takes place in a bioreactor with a volume of 1000 l.
  • the volume of the culture medium used in the method using a 1000 l bioreactor is preferably during the pre-inoculation 50 l to 250 l.
  • the volume of the culture medium is preferably at least 300 l and at most 960 l.
  • the volume of the culture medium in the 1000 l bioreactor is preferably at least 300 l and at most 960 l.
  • the minimum operating volume (V min ) in a bioreactor with the volume of 1000 l according to the invention is preferably between 80 l and 120 l, more preferably the minimum operating volume is 100 l, the maximum operating volume (V) is preferably at least 900 l and at most 1100 l, the maximum operating volume is more preferably 1000 l.
  • the minimum stirred volume is preferably at least 230 l and at most 255 l, more preferably the minimum stirred volume is 245 l.
  • the liquid height at the minimum operating volume (H min ) is in a bioreactor with a volume of 1000 l preferably at least 210 mm and at most 240 mm, more preferably the liquid height at the minimum operating volume is 228 mm.
  • the liquid height at the maximum operating volume (H L ) in a bioreactor with a volume of 1000 l is preferably at least 1500 mm and at most 1900 mm, more preferably the liquid height at the maximum operating volume is 1764 mm.
  • the minimum aspect ratio (H min /T) is preferably at least 0.15 and at most 0.19, more preferably the minimum aspect ration is 0.17.
  • the maximum aspect ratio (H L ⁇ T) for the bioreactor with a volume of 1000 l used in a method according to the invention is preferably at least 1.8 and at most 2.1, more preferably the maximum aspect ratio is 1.96.
  • the freeboard volume is preferably at least 270 l and at most 310 l, more preferably the freeboard volume is 293 l.
  • the freeboard height is preferably at least 450 mm and at most 550 mm, more preferably the freeboard height is 500 mm.
  • the total straight height (H) is preferably at least 1900 mm and at most 2200 mm, more preferably the total straight height is 2045 mm.
  • the height of the upper probe- or sample-ring is preferably at least 900 mm and at most 1200 mm, more preferably the height of the upper probe- or sample-ring is 1093 mm.
  • the height of the lower probe-sample ring is preferably at least 152 mm and at most 286 mm.
  • the method according to the invention takes place in a bioreactor with a volume of 4000 l.
  • the volume of the culture medium used in the method using a 4000 l bioreactor is preferably during the pre-inoculation 1914 l to 3077 l.
  • the volume of the culture medium is preferably at least 2153 l and at most 3846 l.
  • the volume of the culture medium in the 4000 l bioreactor is preferably at least 2153 l and at most 3846 l.
  • the minimum operating volume (V min ) in a bioreactor with the volume of 4000 l according to the invention is preferably between 1500 l and 2200 l, more preferably the minimum operating volume is 1900 l, the maximum operating volume (V) is preferably at least 3800 l and at most 4200 l, the maximum operating volume is more preferably 4000 l.
  • the minimum stirred volume is preferably at least 1500 l and at most 1800 l, more preferably the minimum stirred volume is 1654 l.
  • the liquid height at the minimum operating volume (H min ) is in a bioreactor with a volume of 4000 l preferably at least 800 mm and at most 1200 mm, more preferably the liquid height at the minimum operating volume is 1024 mm.
  • the liquid height at the maximum operating volume (H L ) in a bioreactor with a volume of 4000 l is preferably at least 1800 mm and at most 2200 mm, more preferably the liquid height at the maximum operating volume is 2034 mm.
  • the minimum aspect ratio (H min /T) is preferably at least 0.55 and at most 0.75, more preferably the minimum aspect ration is 0.63.
  • the maximum aspect ratio (H L ⁇ T) for the bioreactor with a volume of 4000 l used in a method according to the invention is preferably at least 1.1 and at most 1.4, more preferably the maximum aspect ratio is 1.25.
  • the freeboard volume is preferably at least 850 l and at most 1250 l, more preferably the freeboard volume is 1039 l.
  • the freeboard height is preferably at least 450 mm and at most 550 mm, more preferably the freeboard height is 500 mm.
  • the total straight height (H) is preferably at least 2000 mm and at most 2400 mm, more preferably the total straight height is 2252 mm.
  • the height of the upper probe- or sample-ring is preferably at least 1200 mm and at most 1600 mm, more preferably the height of the upper probe- or sample-ring is 1403 mm.
  • the height of the lower probe- or sample-ring is preferably at least 500 mm and at most 550 mm, more preferably the height of the lower probe- or sample-ring is 531 mm.
  • the method according to the invention takes place in a bioreactor with a volume of 20 0001.
  • the volume of the culture medium used in the method using a 20 000 l bioreactor is preferably during the pre-inoculation 13 913 l to 17 096 l.
  • the volume of the culture medium is preferably at least 17 391 l and at most 19 231 l.
  • the volume of the culture medium in the 20 000 l bioreactor is preferably at least 20 000 l and at most 21 739 l.
  • the minimum operating volume (V min ) in a bioreactor with the volume of 20 000 l according to the invention is preferably between 9000 l and 16 0001, more preferably the minimum operating volume is 13 0001, the maximum operating volume (V) is preferably at least 19 0001 and at most 25 000 l, the maximum operating volume is more preferably 22 000 l.
  • the minimum stirred volume is preferably at least 8100 l and at most 8500 l, more preferably the minimum stirred volume is 8379 l.
  • the liquid height at the minimum operating volume (H min ) is in a bioreactor with a volume of 20 000 l preferably at least 2100 mm and at most 2500 mm, more preferably the liquid height at the minimum operating volume is 2309 mm.
  • the liquid height at the maximum operating volume (H L ) in a bioreactor with a volume of 20 000 l is preferably at least 3550 mm and at most 3950 mm, more preferably the liquid height at the maximum operating volume is 3777 mm.
  • the minimum aspect ratio (H min /T) is preferably at least 0.70 and at most 0.99, more preferably the minimum aspect ration is 0.83.
  • the maximum aspect ratio (H L ⁇ T) for the bioreactor with a volume of 20 000 l used in a method according to the invention is preferably at least 1.2 and at most 1.5, more preferably the maximum aspect ratio is 1.35.
  • the freeboard volume is preferably at least 5750 l and at most 6500 l, more preferably the freeboard volume is 6131 l.
  • the freeboard height is preferably at least 900 mm and at most 1100 mm, more preferably the freeboard height is 1000 mm.
  • the total straight height (H) is preferably at least 3700 mm and at most 4100 mm, more preferably the total straight height is 3968 mm.
  • the height of the upper probe- or sample-ring is preferably at least 2200 mm and at most 2650 mm, more preferably the height of the upper probe- or sample-ring is 2411 mm.
  • the height of the lower probe- or sample-ring is preferably at least 880 mm and at most 940 mm, more preferably the height of the lower probe- or sample-ring is 913 mm.
  • the preferred seeding ratio used is 11% v/v (1 in 9 dilution) or 20% v/v (1 in 5 dilution), with a preferred feed application of 4% v/v to 25% v/v of the post-inoculation volume.
  • the post-inoculation volume in the 20 000 l bioreactor is preferably adjusted for feed applications up to 15% such that after the addition of all the feeds the final volume at harvest ends up at 20 000 l. However, for feed applications greater then 15% v/v the post-inoculation volume is preferably adjusted for a 15% v/v feed but following the application of feeds the final pre-harvest volume will be a minimum of 20 000 l and a maximum 22 000 l.
  • the 20 000 l bioreactor is expected to hold a total of 20 000 l to 22 000 l at the end of a batch.
  • the bioreactor with a volume of 20 000 l is preferably operated in batch or fed batch mode for 10 to 15 days.
  • the invention also includes a bioreactor system for the cultivation of mammalian cells characterised in that a) a first bioreactor with a volume of at least 500 l, preferably of at least 1000 l, is connected with b) a second bioreactor with a volume of at least 2000 l, preferably of at least 4000 l, which has a volume greater than the first bioreactor and wherein the second bioreactor with a volume of at least 2000 l, preferably of at least 4000 l, is connected with c) a third bioreactor according to the invention having a volume of at least 10 000 l, preferably of at least 20 000 l, which has a volume greater than the second bioreactor.
  • the bioreactor system is characterised in that at least one of the bioreactors is a bioreactor according to the invention. More preferably, all of the bioreactors of the bioreactor system are bioreactors according to the invention.
  • Bioreactors according to the invention are in this context all bioreactors described in this description, in the examples and in the claims.
  • the bioreactor system according to the invention is also called bioreactor train or device.
  • the bioreactor train comprises preferably different bioreactors, which are also called stage.
  • the bioreactor with a volume of at least 500 l, preferably of at least 1000 l corresponds to stage N-3 and/or N-2.
  • the bioreactor with a volume of at least 2000 l, preferably of at least 4000 l corresponds to stage N-1.
  • the bioreactor with a volume of at least 10 000 l, preferably of at least 20 000 l corresponds to stage N.
  • the design of the bioreactor train is based on the need to ensure a homogenous environment with respect to process parameters such as pH, dissolved oxygen tension (DOT) and temperature, maintaining a well mixed cell suspension and blending nutrient feeds within the bioreactor.
  • the bioreactors of the bioreactor train preferably show geometric similarity. This allows a scale-down model to develop, for example at 12 l laboratory scales or 500 l pilot scales.
  • the bioreactors of the stages N-3, N-2 and N-1 are used as seed-bioreactors.
  • Bioreactor of stage N is used as a production-bioreactor.
  • the design of the seed- and production-bioreactors is preferably based on the same principles. However, some departures can be required to allow for flexibility in processing.
  • the aspect ratio H L /T is at least 0.17 and at most 1.96.
  • bioreactor especially a 50 l bioreactor corresponding to stage N-4.
  • the N-4 bioreactor is a S-200 seed wave bioreactor or a 100 l stirred tank reactor
  • liquids for example culture medium
  • pneumatic assisted flow or by peristaltic pumps can be transported from one bioreactor to another bioreactor by pneumatic assisted flow or by peristaltic pumps.
  • the invention also includes a method to cultivate and propagate mammalian cells, characterised in that a) at least one mammalian cell is cultivated under suitable conditions and in a suitable culture medium in a first bioreactor with a volume of at least 500 l, preferably with a volume of at least 1000 l, b) the medium containing the cells obtained by propagation from the at least one mammalian cell is transferred into a second bioreactor with a volume of at least 2000 l, preferably with a volume of at least 4000 l, c) the transferred cells are cultivated in the second bioreactor with a volume of at least 2000 l, preferably with a volume of at least 4000 l, d) the medium containing the cells obtained in step c) is transferred into a third bioreactor with a volume of at least 10 000 l, preferably with a volume of at least 20 000 l, and e) the transferred cells are cultivated in the third bioreactor with a volume of at least 10 000 l,
  • the method is characterised in that at least one of the bioreactors used is a bioreactor according to the invention, more preferably all bioreactors used are bioreactors according to the invention.
  • Bioreactors according to the invention are in this context all bioreactors described in this description, in the examples and in the claims.
  • the bioreactor of step e) is preferably operated in batch or fed batch mode.
  • the cells are cultivated in step e) preferably for 10 to 15 days.
  • Step a) is also called stage N-3 and/or N-2.
  • Step c) is also called stage N-1.
  • Step e) is also called stage N.
  • the cultivation conditions in the bioreactors of steps a), c) and e) are the same. More preferably, the cultivation conditions in the bioreactors of steps a), c) and e) have a homogenous environment with respect to process parameters such as pH, dissolved oxygen tension and temperature. Preferably pH, dissolved oxygen tension and temperature in the bioreactors of steps a), c) and e) are the same.
  • the seeding ratio after the transfer steps b) and/or d) is at least 10% v/v, more preferably at least 11% v/v (1 in 9 dilution) and at most 30% v/v, more preferably 20% v/v (1 in 5 dilution).
  • the total medium or only a part of the medium are transferred in steps b) and d).
  • FIG. 1 shows a bioreactor according to the invention.
  • 1 is the bioreactor.
  • 10 is the diameter of the tank (T).
  • 20 is the total straight height of the bioreactor (H).
  • 30 is the base height of the bioreactor (H b ).
  • 40 is the head height of the bioreactor (H h ).
  • 50 is the liquid height at the maximum operating volume (H L ).
  • 60 is the top impeller diameter (D top ).
  • 68 is the top impeller.
  • 70 is the bottom impeller diameter (D bottom ) .
  • 78 is the bottom impeller.
  • 80 is the clearance between tank bottom and centre line of the bottom impeller (D c ).
  • 90 is the impeller separation (D s ).
  • 100 is the clearance of the top impeller below the liquid surface (D o ).
  • 108 is a sparger.
  • 110 is the sparger to tank bottom clearance (S c ).
  • 120 is the sparger to bottom impeller clearance (D c ⁇ S c ).
  • 128 is a baffle.
  • 138 is a port located at the lower ring.
  • 148 is a port located at the centre-line of the top impeller 68.
  • FIG. 2 shows a bioreactor system of the present invention.
  • 111 is a bioreactor with a volume of 1000 l.
  • 11 is a bioreactor with a volume of 4000 l.
  • 1 is a bioreactor according to the invention with a volume of 20 000 l.
  • the 20 000 l bioreactor is operated in batch and fed batch mode for 10 to 15 days for the cultivation of mammalian cells.
  • the mammalian cells are kept in a homogeneous suspension by agitation via an impeller system.
  • the vessel geometry for the 20 000 litre bioreactor was determined by an iterative design basis in which the maximum working volume, freeboard straight side distance, aspect ratio H L /T and impeller to tank diameter, D/T ratio are altered until an acceptable aspect ratio is achieved.
  • Table 2 describes the aspect ratios in the 20 000 litre bioreactor at various operating volumes during normal processing. The aspect ratios have been tested at 500 litre scale and provided the superficial gas velocity and power per unit volume are kept constant the K L a remains constant.
  • the tank diameter is altered to obtain the optimal aspect ratio H L /T. Changes to tank internal diameter (ID) are limited by acceptable aspect ratio and plant footprint.
  • ID is 2.794 m.
  • Tank height is determined from the maximum operating volume, aspect ratio H L /T, freeboard straight side length, base and top plate design.
  • the final tank height is a compromise value determined from volumetric contingency for foam, plant height and impeller shaft length.
  • the tank height from base to head tan line is 4.933 m.
  • the freeboard height is defined as the length of straight side above the liquid head when the bioreactor is filled to it's maximum operating volume. This is determined by taking into account the extent of:
  • the selection of head and base plate design was made with a consideration for desired mechanical strength, free draining clean design and fluid flow. Maintaining consistent plate design between scale down and full scale will contribute towards maintaining geometric similarity.
  • the base plate is of American Society of Mechanical Engineers Flanged and Dished (ASME F&D) design.
  • the head-plate design accommodates a manway or a flanged head plate to allow access/removal of the impellers.
  • the agitation of the bioreactor is to achieve rapid mixing, maintain homogeneity, maintain mammalian cells in suspension and gas bubble dispersion.
  • the underlying issue with achieving the above objectives is minimising cell damage through shear forces originating from impeller geometry and eddies or vortices created behind the impeller blades. A compromise of the above objectives can be achieved by selection of an appropriate impeller type.
  • Top-entry impeller shafts tend to be longer than bottom-entry, which results in the shaft being heavier and larger diameter. Additionally the shaft length together with the inherent clearance between the two faces of the mechanical seal may dictate the requirement for steady bearings or stabilising ring to prevent excessive “shaft wobble”. Service and maintenance are affected by the available space around the agitator, gearbox and seal assembly, and on-site shaft installation and removal is limited by plant height.
  • the submerged seal complicates the design of a free draining bioreactor by compromising the position of the harvest drain valve. Secondly the diameter of the harvest nozzle may be restricted thus restricting the flow rate of harvest stream. Therefore a top entry impeller shaft is used in the 20 000 litre bioreactor.
  • baffle requirement for centre mounted impeller is critical to prevent vortex formation.
  • the critical issues related to baffles are baffle number, baffle width (W), baffle length (H baffle ) and baffle to tank wall clearance (W c ).
  • baffles that are 0.1 ⁇ T or 279 mm wide 1.1 ⁇ H ⁇ H h or 3882 mm tall and have a baffle to tank wall clearance, W c of 0.01 ⁇ T or 28 mm.
  • baffle The thickness of baffle is not specified but the thickness needs to ensure rigidity to the radial component of the fluid flow. Additionally thickness needs to ensure the baffle plates are not warped during SIP thereby affecting the baffle to tank wall clearance.
  • High shear, such as Rushton (or Rushton-type), impellers offer high power dissipation for gas dispersion but lack in axial flow necessary for mixing and homogeneity. Additionally, agitation from high shear impellers suffers from dangers of excessive cell damage.
  • Table 4 shows the impellers tested at lab scale (12.2 litre) that gave equivalent hydrodynamic and cell growth performance.
  • the hydrofoil is mounted above the high solidity pitched blade impeller.
  • the Lightnin A310 and A315 at the D/T ratio described in table 4 are used in the bioreactor.
  • Impeller types short-listed for scale down study Impellers D/T ratio 1 N p / 2 N q Vendor Description A310 0.44 0.30/0.56 Lightnin Three bladed hydrofoil design A315 0.46 0.75/0.73 Lightnin Four pitched- bladed high solidity impeller SC-3 0.40 0.90/0.90 Chemineer Three bladed hydrofoil design 3HS39 0.46 0.53/0.58 Philadelphia Four pitched- Mixers bladed high solidity impeller 1 N p is characteristic impeller power number. It is a measure of an impeller efficiency to impart the kinetic energy of the rotating impeller blades to the fluid. It is important in quantifying the gas dispersion 2 N q is characteristic impeller flow number. It is a measure of pumping ability of the impeller and is important in quantifying fluid bulk movement.
  • the diameter for axial flow impellers is recommended to be less than 0.5 ⁇ T. A diameter greater than this results in disruption in axial flow, hence poor agitation and aeration.
  • the K L a scale up correlation at 12.2 litre has been determined for the four impellers at the D/T ratios shown in table 4. From a geometric similarity standpoint A310 diameter of 1.229 m (D/T of 0.44) and A315 diameter of 1.285 m (D/T of 0.46) is recommended. However a manway diameter can restrict the largest impeller diameter that can be installed and removed to 1.219 m. Therefore A310 and A315 to be 1.219 m diameter are used thereby keeping with ease of impeller installation and removal and maintaining close to the geometric similarity proposed in scale down study.
  • the spacing between impellers in a bioreactor with multiple impellers is an important dimension to consider.
  • the ungassed power consumption is equivalent to a single impeller when the dual impeller are spaced less then 0.5 ⁇ D along the shaft.
  • the power consumption becomes adductive.
  • efficiency of the impeller is reduced when the impeller spacing becomes less then 0.5 ⁇ D and the requirement for multiple impellers becomes unnecessary.
  • impeller spacing also impacts on the potential of creating dead zones (poorly mixed zones) within the bioreactor.
  • An additional constraint on the choice of impeller spacing is discrete working volumes required within the bioreactor.
  • the impeller spacing, D s of 1.229 ⁇ D bottom (1498 mm) allows both impellers to remain submerged at the lowest post-inoculation volume of 17392 litres with liquid head above the upper impeller, D o , of 0.5 ⁇ D top (615 mm) and off bottom clearance, D C , of 0.75 ⁇ D bottom (913 mm).
  • Table 5 highlights volumes that will form liquid surfaces or lower liquid cover, above the impellers. Agitation needs to be modified to avoid foaming at these critical volumes.
  • Table 7 specifies the agitation rate for the 20 000 litre bioreactor.
  • the bioreactor is agitated typically at 20-260 W/m 3 , preferably at 55-85 100 W/m 3 .
  • the agitation strategy is being developed during the 500 litre pilot fermentations.
  • the agitation rate of 0 to 80 ⁇ 1 rpm is therefore used as an operational range.
  • the dry type seal (John Crane—5280D type) will produce 3 g per year of shedding (seal face and seal seat material) composed of resin impregnated carbon. This is based on continuous 24 hour operation over a year. The amount of shedding for the wet seal is significantly less. Therefore a wet condensate-lubricated seal is adopted for all bioreactor double seals.
  • the aeration duty of the 20 000 litre bioreactor is governed by:
  • the 20 000 litre bioreactor is designed to provide K L a values of up to 20 h ⁇ 1 for processes with oxygen uptake rates of 5 mmol ⁇ L ⁇ 1 ⁇ h ⁇ 1 .
  • the bioreactor design needs to be flexible enough to allow cultivation of processes reaching 20 ⁇ 10 6 cells ⁇ mL ⁇ 1 .
  • the aeration requirement can be achieved by a number of different approaches. However the use of a fluted sparger with air and oxygen enrichment to make up any deficit in oxygen transfer rate (OTR) during peak oxygen demand was used. The advantages of this approach are:
  • bioreactor aeration design must have the flexibility to be modified to meet the desired K L a.
  • Table 8 describes the gassing requirements for the 20 000 litre bioreactor. The gas flow rates were scaled up on constant superficial gas velocity.
  • the main or “DOT control” sparger supplied by dual range clean air, mass flow controller (MFC) and oxygen MFC with gas flow metered via a DOT control loop and a CO 2 MFC metering gas via the acid pH control loop.
  • MFC mass flow controller
  • oxygen MFC oxygen MFC with gas flow metered via a DOT control loop and a CO 2 MFC metering gas via the acid pH control loop.
  • the dual range MFC's are used to achieve precise flow control at the extreme ends of the desired operating ranges.
  • the second or “ballast” sparger is supplied by a CA MFC to which nitrogen is also supplied. It was measured that early DOT control requires small nitrogen ballast to assist in early DOT demand and lower the DOT to set point.
  • the ballast sparger also meters ballast air to facilitate stripping out excess pCO 2 .
  • the headspace purge is used to allow removal of CO 2 and oxygen from the headspace. This is to facilitate better pH and pCO 2 control and dilution of high oxygen blend prior to exhausting to environment.
  • the ability to vary headspace flow rate allows design of gassing strategy for various processes requiring different blends of oxygen enrichment and control point pCO 2 .
  • the bioreactor ports for sparger installation are designed to fit pipe design of diameter of 51 mm.
  • the position of port should allow the placement of control sparger (D c ⁇ S c ) at a distance of 320 mm below the bottom edge of the lower impeller and no greater 593 mm from tank bottom (S c ).
  • ballast sparger A separate port for the installation of the ballast sparger was also built.
  • the position of this port allows the placement of ballast sparger at a distance of 320 mm, (D c -S c ) below the bottom edge of the lower impeller and no greater then 593 mm from tank bottom (S c ).
  • the requirement to add ballast from a separate sparger is due to three reasons:
  • a ring sparger of 0.8 ⁇ D bottom (80% diameter of bottom A-315 impeller diameter) is used to distribute the holes under the blades and not the impeller hub.
  • the CIP and installation of this configuration is difficult. Therefore selection of sparger geometry that permits distribution of the desired number of holes in a manner that is consistent with best to distribute the holes and sanitary design can be used also.
  • the curvature of the crescent is 0.8 ⁇ D bottom .
  • the crescent circumference is 240° of the complete circumference of 0.8 ⁇ D bottom ring, this is 1077 mm.
  • the DOT control sparger is 1077 mm long and has a 51 mm diameter.
  • the holes have a 4 mm diameter.
  • a total of 250 holes divided into 2 rows (2 ⁇ 125) at 45° from the dorsal (vertical) are used. Drain holes of 4 mm diameter on both ends of the sparger are drilled on the ventral side of the sparger to aid free CIP drainage of the sparger.
  • the ballast sparger is 1077 mm long and of 51 mm diameter and has a total of 100 6 mm diameter holes in a single dorsal row. Drain holes of 4 mm diameter on both ends of the sparger are drilled on the ventral side of the sparger to aid free CIP drainage of the sparger.
  • the probe ring position must be placed in a well-mixed representative region of the bioreactor. Additional considerations included working volume range and ergonomic operations. The location of probe ports, sample valve and addition points were considered together to avoid transitory spikes. Furthermore the position of the sample valve with respect to controlling probes needs to permit accurate estimation of off-line verification of the measured process parameter. This is shown in table 10.
  • the sample port design allows a representative sample to be taken from the bioreactor. Therefore any residual material must be as small as possible.
  • the samples taken are used to determine off line checks for dissolved gases, pH, nutrients and biomass concentration.
  • the orifice of the port opening is large enough to prevent sieving causing biomass aggregates to be retained.
  • the 2 mm orifice NovaSeptum sampling device was used. However this has to be balanced with the desire to keep residual volume of the port low.
  • the port needs to be positioned in a well-mixed zone adjacent to the probes that need to be verified by off-line checks and will be determined via nozzle position (see table 10).
  • the production bioreactor has three 2500 litre nominal volumes add tanks.
  • the add tanks are filled at 25 l/min.
  • the flow rate of feeds from the add tanks to the bioreactor is controlled at 0.2 to 1.0 millilitres of feed per litre of post-inoculation bioreactor volume per hour (ml/l/h). It is expected that feed rate is controlled at ⁇ 5% of set point.
  • the production bioreactor is serviced by three 1372 mm ID by 1880 mm add tanks. These tanks have the capability to be cleaned and sterilised independently and together with the production bioreactor.
  • Access into the bioreactor is required for certain service operations. Access can be gained by considering a flanged head plate or incorporation of a manway into the head plate.
  • the need for access into the bioreactor is for:
  • the size of the manway must be sufficient to allow access for the above objectives.
  • the manway used was of sufficient diameter to allow the removal of two impellers of 1219 mm diameter.
  • the design ensures that any sensor gives sufficient precision in volume measurement around the operating range.
  • the volume measurement in bioreactor is able to measure a range of 13 000 to 25 000 litres.
  • the sensor sensitivity needs to be at least 0.5% of full span.
  • volume measurement in the feed add-tanks and alkali tank is able to measure 0 to 2200 and 2500 litres respectively.
  • the sensor sensitivity needs to be at least 0.2% of full span. This will permit hourly verification of feed flow rate at the minimum flow rate of 0.2 ml/l per hour or 3.51 per hour by measuring the volume decrease in the add tanks.
  • the medium is brought to operating temperature and pH by process control. This is achieved by “gentle” heating of the jacket (avoid high temperature at vessel wall).
  • the temperature control range during operation is 36 to 38° C. with an accuracy of ⁇ 0.2° C. at set point.
  • the bioreactor jacket area is specified with the following considerations in mind:—
  • the process pH is monitored and controlled with probes connected via a transmitter to a DCS based process controller.
  • the process is be controlled by addition of CO 2 to bring the pH down to set point and addition of alkali to bring pH up to set point. pH is controlled at ⁇ 0.03 of set point.
  • Alkali is added through two addition points to distribute the alkali. This ensures quicker blending of alkali in the event of long re-circulation time in the tank.
  • the CO 2 is added via the control sparger.
  • Control and back-up probes are located in the lower port ring at 913 mm (see table 10) from tank bottom. Additionally the pH probes are located diametrically opposite the alkali addition points into the bioreactor.
  • Dissolved oxygen is monitored and controlled with polarographic DOT probe.
  • the DOT set point maintained by sparging:
  • Cascade DOT control allows DOT set point to be maintained through changes in the ballast and demand gas in conjunction with ramping of agitator speed.
  • DOT is considered together with pCO 2 control for those processes where metabolic CO 2 is liberated.
  • DOT is controlled at ⁇ 2% of set point. Control and back-up probes are located in the lower port ring at 913 mm from tank bottom.
  • the process dCO 2 is monitored with an pCO 2 probe and excess dCO 2 is stripped by gassing CA through the ballast sparger. The optimal position for this probe is close to the pH probes.
  • the feeds (SF22 and amino acid) are high in pH and osmolality. Therefore bolus additions need to be avoided to maintain good pH control. However the control of desired flow rates ( ⁇ 5% of set point) is technically challenging. Therefore an addition strategy that encompasses point of addition with delivery mode avoids the circulation of feed bolus and potential variations of pH control.
  • Antifoam (C-emulsion) addition is added as required to maintain the bioreactor liquid surface free of foam.
  • a working stock of 1 in 10 diluted C-emulsion can be dosed on the liquid surface.
  • the antifoam suspension is continuously agitated in the storage container to prevent partitioning. It is important to dose the antifoam close to the centre of the tank to diminish the effects of the radial component of the fluid flow carrying the antifoam to the tank walls where it will adhere. Therefore the addition point is 0.25 ⁇ T toward the tank centre or 699 mm from tank centre.
  • the vessel geometry for the 4000 litre bioreactor was determined by an iterative design basis in which the maximum working volume, freeboard straight side distance aspect ratio (H L /T) and impeller to tank diameter ratio (D/T) are altered until an acceptable aspect ratio is achieved.
  • Table 11 describes the aspect ratios in the 4000 litre bioreactor at the various operating volumes during normal processing. These aspect ratios arise from the selection of tank ID and the operating volume required. From a processing perspective the mixing requirements at the three operating conditions are different. During pre-inoculation stage the bioreactor mixing is important to allow medium to equilibrate with minimal K L a requirement. However for post-inoculation and pre-transfer stages both mixing and K L a are important considerations. Therefore both these features were tested at the aspect ratio range.
  • the tank diameter was altered to obtain the optimal aspect ratio H L /T. Changes to tank internal diameter are limited by acceptable aspect ratio and plant footprint.
  • the tank ID is 1626 mm.
  • Tank height is determined from the maximum operating volume, aspect ratio H L /T, freeboard straight side length, base and top plate design.
  • the final tank height is a compromise value determined from volumetric contingency for foam, plant height and acceptable impeller shaft length.
  • the head to base tan line height is 2817 mm.
  • the freeboard height of 500 mm (1039 litre or 27% v/v of the maximum operating volume) is used for this seed bioreactor.
  • the base and head plate design is a ASME F&D design for this seed bioreactor.
  • the agitation of the bioreactor is to achieve rapid mixing, maintain homogeneity, maintain mammalian cells in suspension and gas bubble dispersion.
  • the underlying issue for achieving the above objectives is minimising cell damage through shear forces originating from impeller geometry and eddies or vortices created behind the impeller blades. A compromise of the above objectives was achieved by selection of an appropriate impeller type.
  • the motor drive is top mounted for the benefits already highlighted.
  • baffle requirement for centre mounted impeller is critical to prevent vortex formation.
  • the critical issues related to baffles are baffle number, baffle width (W), baffle length (H baffle ) and baffle to tank wall clearance (W c ).
  • baffles that are 0.1 ⁇ T or 163 mm wide 1.1 ⁇ H ⁇ H h or 2195 mm tall and have a baffle to tank wall clearance, W c of 0.01 ⁇ T or 16 mm were used.
  • the thickness of the baffles is not specified but the thickness needs to ensure rigidity to the radial component of the fluid flow. Additionally thickness needs to ensure the baffle plates are not warped during SIP thereby affecting the baffle to tank wall clearance.
  • the impellers for this bioreactor are identically formed to the 20000 litre vessel and have a identical D/T ratio of 0.44.
  • the bottom impeller is a Lightnin's A315 at 710 mm of diameter and the top impeller is a Lightnin's A310 at 710 mm of diameter.
  • the impeller spacing, D s between the centre-line of the top impeller and the centre-line of the lower impeller is 1.229 ⁇ D bottom or 872 mm.
  • the off bottom impeller clearance, D c is 0.75 ⁇ D bottom or 531 mm. This allows the lower impeller to remain submerged at the lowest post-inoculation volume of 2153 litres and both impellers submerged at 3367 litres with liquid head above the upper impeller (D o ) of 0.5 ⁇ D top or 358 mm.
  • Table 12 highlights the volumes that will form liquid surfaces or lower liquid cover above the impeller. Agitation can be modified to avoid foaming at these critical volumes.
  • the 4000 l bioreactor can operate at two discrete post-inoculation volumes with either the lower impeller submerged (during cultivation of 1 in 9 seeding process) or with both impellers submerged (during 1 in 5 seeding process), table 13 shows the liquid cover obtained for the upper and lower impeller during its operation.
  • a liquid cover of 0.67 to 0.82 ⁇ D bottom above the lower A315 impeller is observed during cultivation of the 1 in 9 seeded processes. This is within the recommendations of 0.5 to 1 ⁇ D.
  • a liquid cover of 0.06 to 0.78 ⁇ D top above the top A310 impeller is observed during cultivation of 1 in 5 seeded process.
  • the lower liquid cover is outside the recommendation. However this liquid cover is observed during pre-inoculation when mixing and agitation are less critical.
  • Table 14 specifies the agitation rate for the 4000 litre bioreactor.
  • the bioreactor will be agitated typically at 20-260 W/m ⁇ 3 , preferably at 55-85 W/m ⁇ 3 .
  • the agitation strategy was developed during the 500 litre pilot fermentations. An agitation rate of 0 to 88 ⁇ 1 rpm is therefore used as an operational range.
  • a double mechanical seal that is condensate lubricated is used as described.
  • Table 15 shows the gas flow, based upon scale up of constant superficial gas velocity, for DOT and pH control during the inoculum expansion in the 4000 litre bioreactor.
  • Oxygen is not required for DOT control. However oxygen enriched air can be used to facilitate lower gassing to prevent excess foaming. It is recommended that a smaller range N 2 MFC should supply nitrogen for early DOT control and reducing deviant, high levels of DOT.
  • Table 16 show the key sparger design specification for the 4000 litre bioreactor.
  • the sparger length, S L of 568 mm is determined for pipe geometry.
  • the holes are distributed on either end of the sparger to prevent bubble liberating directly under the A315 hub. Alternatively a crescent geometry can be used.
  • the pipe diameter is selected to aid spacing of the desired number of holes. The diameter is 38 mm.
  • the 100 2 mm holes are located on the dorsal surface of the sparger with a single 2 mm hole located on the ventral surface to aid free CIP drainage of the sparger.
  • the bioreactor port for sparger installation is designed to a fit pipe design of diameter of 38 mm.
  • the position of the port allows the placement of a control sparger at a distance of 194 mm, D c -S c below the bottom edge of the lower impeller and no greater 337 mm from tank bottom, S c .
  • the 4000 litre bioreactor has been designed to accept two subsurface feeds and alkali that need to be discharged in well-mixed area of the bioreactor.
  • the foam is controlled by surface addition of 1 in 10 diluted C-emulsion.
  • a single spare above surface addition port directed to the vessel wall is also designed for future flexibility.
  • the splashing of culture onto the surface of the medium during inoculation of the seed bioreactor can be avoided to prevent build up of foam. Therefore the inoculum addition port is above surface and directed to the vessel wall.
  • the use of the harvest port in the base plate is the ideal port for removal of inoculum during transfer of inoculum.
  • the medium addition port is directed to the vessel wall.
  • the total addition ports are:
  • sample port design is similar to that specified for the 20 000 litre bioreactor.
  • the level sensor is able to measure up to 4000 litres with an accuracy ⁇ 0.5% of full span.
  • the 1914 to 3077 litre of medium are brought to operating temperature, typically 36.5° C. by process control. This is achieved by “gentle” heating of the jacket and avoid high temperature at vessel wall.
  • the bioreactor jacket area is specified with the following considerations in mind:
  • the process pH is monitored and controlled with probes connected via a transmitter to a DCS based process controller.
  • the process pH is controlled by addition of CO 2 through the control sparger to bring the pH down to set point and addition of alkali to bring pH up to set point.
  • Alkali is added through at least one subsurface port at centre-line of the bottom impeller.
  • the CO 2 will be added via the control sparger.
  • Control and backup probes are in the lower port ring at 531 mm from tank bottom as shown in table 17.
  • Dissolved oxygen is monitored and controlled with polarographic DOT probe.
  • the DOT set point maintained by sparging:
  • DOT control allows DOT set point to be maintained through interchangeable use of oxygen or air as demand gas. It is not envisaged that pCO 2 control is required in the inoculum bioreactor. Control and backup probes are in the lower port ring at 531 mm from tank bottom as shown in table 17.
  • the point of addition is 531 mm from tank bottom, in the plane of the centre-line of the lower impeller to assist in the rapid dissipation of feed bolus.
  • the addition point is at surface projecting 0.25 ⁇ T toward the tank centre or 407 mm from centre of tank.
  • the vessel geometry for the 1000 litre bioreactor was determined by an iterative design basis in which the maximum working volume, freeboard straight side distance, aspect ratio (H L /T) and impeller to tank diameter ratio (D/T) are altered until an acceptable aspect ratio is achieved.
  • Table 18 describes the aspect ratios in the 1000 litre bioreactor at various operating volumes during normal processing. These aspect ratios arise from the selection of tank ID and the operating volume required. From a processing perspective the mixing requirements at the different operating conditions are different. During pre-inoculation stage the bioreactor mixing is important to allow medium to equilibrate with minimal K L a requirement. However with post-inoculation and pre-transfer stages both mixing and K L a are important considerations. Therefore both of these features were tested at the aspect ratio range.
  • the tank diameter is altered to obtain the optimal aspect ratio H L /T. Changes to tank internal diameter are limited by acceptable aspect ratio and plant footprint.
  • the tank ID is 0.864 m.
  • the tank height is determined from the maximum operating volume, aspect ratio H L /T, freeboard straight side length, base and top plate design.
  • the final tank height is a compromise value determined from volumetric contingency for foam, plant height and acceptable impeller shaft length.
  • the head to base tangent line height is 2.347 m.
  • the freeboard height of 500 mm (293 litres or 31% v/v of the maximum operating volume) is used for this seed bioreactor.
  • the base and head plate design is ASME F&D for this seed bioreactor.
  • Agitation of the bioreactor is to achieve rapid mixing, maintain homogeneity, maintain mammalian cells in suspension and gas bubble dispersion.
  • the underlying issue with achieving the above objectives is to minimise cell damage through shear forces originating from impeller geometry and “eddies” or vortices created behind the impeller blades.
  • a compromise of the above objectives was achieved by selection of an appropriate impeller type and gassing strategy.
  • the motor drive is top mounted for the benefits as already highlighted.
  • baffle requirement for a centre mounted impeller is critical to prevent vortex formation.
  • the critical issues related to baffles are baffle number, baffle width (W), baffle length (H baffle ) and baffle to tank wall clearance (W c ).
  • baffles that are 0.1 ⁇ T or 86 mm wide 1.1 ⁇ H ⁇ H h or 2099 mm tall and have a baffle to tank wall clearance, W c of 0.01 ⁇ T or 9 mm were used.
  • baffle The thickness of baffle is not specified but the thickness needs to ensure rigidity to the radial component of the fluid flow. Additionally thickness needs to ensure the baffle plates are not warped during SIP thereby affecting the baffle to tank wall clearance.
  • the impellers for the 1000 l bioreactor should be identical formed to the 20 000 litre vessel with an identical D/T ratio. Therefore the bottom impeller is a Lightnin's A315 at 381 mm diameter and the top impeller is a Lightnin's A310 at 381 mm diameter.
  • the impeller spacing (D s ) between the centre-line of the top impeller and the centre-line of the bottom impeller is 2 ⁇ D bottom (762 mm).
  • the off bottom impeller clearance (D c ) is 0.4 ⁇ D bottom (152 mm). This allows the bottom impeller to remain submerged with liquid cover (D o ) of 0.5 ⁇ D bottom or 190 mm at the lowest post-inoculation volume of 167 litres and both impeller submerged at 616 litres with liquid head above the upper impeller, D o , of 0.5 ⁇ D top (190 mm).
  • Table 19 highlights volumes that will form liquid surfaces or lower liquid cover above the impeller Agitation can be modified to avoid foaming at these critical volumes.
  • the 1000 l bioreactor operates at two discrete post-inoculation volumes with either the bottom impeller submerged during the 1 in 5 processes and 1 in 9 processes or with both impellers submerged during the N-2 phase of the 1 in 5 process and rolling seed operations for both 1 in 5 and 1 in 9 processes.
  • Table 20 shows the liquid cover above the upper and lower impeller during operation of the 1 in 5 and 1 in 9 sub-cultivation processes.
  • the liquid cover above the lower impeller falls below 0.5 ⁇ D. It is therefore important to reduce the agitation rate, to avoid surface gas entrainment, whilst operating at this low volume.
  • a liquid cover, (D o ) of 2.05 ⁇ Dtop is obtained.
  • K L a has been shown not to be adversely affected and bulk blending is not an issue.
  • Table 21 specifies the agitation rate for the 1000 litre bioreactor.
  • the bioreactor is agitated at around 20-260 W/m 3 , preferably at 55-85 W/m 3 .
  • the agitation strategy was developed during the 500 litre pilot fermentations.
  • An agitation rate of up to 155 ⁇ 1 rpm is used as an operational range.
  • Table 22 shows the gas flows based upon scale up of constant superficial gas velocity, for DOT and pH control during the inoculum expansion in the 1000 litre bioreactor.
  • Oxygen will not be required for DOT control. However oxygen enriched air may be used to facilitate lower gassing to prevent excess foaming. It is recommended that the smaller range CA MFC should be used to delivery nitrogen for early DOT control and reducing deviant, high levels of DOT.
  • Table 23 shows the key sparger design specification for the 1000 litre bioreactor.
  • the sparger length, S L of 305 mm is determined for pipe geometry.
  • the holes are distributed on either end of the sparger to prevent bubble liberating directly under the A315 hub. Alternatively a crescent geometry can be considered.
  • the pipe diameter is 25 mm.
  • 30 2 mm holes are located on the dorsal surface of the sparger with a single 2 mm hole located on the ventral surface to aid free CIP drainage of the sparger.
  • the bioreactor port for sparger installation is designed to fit pipe design of diameter of 25 mm.
  • the position of port allows the placement of control sparger at a distance of 88 mm (D c ⁇ S c ) below the bottom edge of the bottom impeller and no greater than 64 mm from tank bottom (S c ).
  • N/A Diametrically opposite plate 2. 135° vent out Exhaust vent out Head 38.1 (1.5′′) 1. N/A Diametrically opposite plate 2. 315° overlay gas in Transfer valve Base 50.8 (2.0′′) 1. N/A NovAseptic type to plate 2. Centre allow free draining Media inlet Head 76.2 (3′′) 1. N/A Directed into vessel plate 2. 310° wall Inoculum transfer Head 50.8 (2.0′′) 1. N/A Directed into vessel from S200 to plate 2. 320° wall 1000 L CIP - Spray ball Head 76.2 (3′′) 1. N/A CIP'ing of highest plate 2. 270° point CIP - Spray ball Head 76.2 (3′′) 1. N/A plate 2.
  • the probes and port ring In order to monitor, control and sample from a volume of 50 l, the probes and port ring needs to be 151 mm from tank bottom. However the probe/port ring cannot be located this low as it falls on the weld of the base plate and the straight cylindrical side of the bioreactor.
  • the probe and port ring has been specified at 286 mm from tank bottom. This permits a volume of 134 litres to be monitored, controlled and sampled.
  • the probes/port ring is located as close to the tank bottom as permitted to minimise the monitored/controlled volume.
  • the 1000 litre bioreactor has been designed to accept two subsurface feeds and alkali to be discharged into a well-mixed area of the bioreactor.
  • the foam is controlled by surface addition of 1 in 10 diluted C-emulsion.
  • a single above surface spare addition port directed to the vessel wall was also integrated for future flexibility.
  • the splashing of culture on to the surface of the medium during inoculation of seed bioreactor should be avoided to prevent build up of foam. Therefore the inoculum addition port is above surface and directed to the vessel wall.
  • the use of the harvest port in the base plate is the ideal port for removal of inoculum during transfer of inoculum. Additionally the medium addition port is directed on to the vessel wall.
  • the total addition ports are:
  • the sample port design is similar to that specified for the 20 000 litre bioreactor.
  • the sample port is located 286 mm from tank bottom to minimise the volume that can be sampled.
  • the level sensor is able to measure up to 1000 litres.
  • the level sensor sensitivity is at least 0.25% of full span.
  • the 250 to 800 litres of medium is brought to operating temperature, typically 36.5° C. during initial inoculation and “seed rolling operation” by process control. This is achieved by “gentle” heating of the jacket and avoid high temperature at vessel wall.
  • the bioreactor jacket area is specified with the following considerations in mind:
  • the process pH is monitored and controlled with probes connected via a transmitter to a DCS based process controller.
  • the process pH is controlled by addition of CO 2 to bring the pH down to set point and addition of alkali to bring pH up to set point.
  • Alkali is added through at least one subsurface port at centre-line of the bottom impeller.
  • the CO 2 is added via the control sparger.
  • control and back up probes are in the lower port ring at 286 mm from tank bottom to minimise the volume that can be monitored as shown in Table 24.
  • Dissolved oxygen is monitored and controlled with polarographic DOT probe.
  • the DOT set point maintained by sparging:—
  • DOT control allows DOT set point to be maintained through interchangeable use of oxygen or air as demand gas.
  • Control and back up probes are in the lower port ring at 286 mm from tank bottom minimise the volume that can be monitored, as shown in table 24.
  • the point of addition is 286 mm from tank bottom, in the vicinity of the centre-line of the bottom impeller to assist in the rapid dissipation of feed bolus.
  • the addition point is at surface projecting 0.25 ⁇ T toward the tank centre or 216 mm from tank centre.
  • the bioreactor design is based on the ability to perform both 1 in 5 (20% v/v) and 1 in 9 (11% v/v) subculture ratios.
  • the bioreactor train consists of a 1000 litre (Stages N-3 and N-2) and 4000 litre (Stage N-1) seed bioreactors followed by a 20 000 litre production bioreactor (Stage N).
  • the operating volumes for each bioreactor are defined in examples 1 to 3.
  • the bioreactors are based on a stirred tank design and a top driven agitator system was used.
  • the design is based on the need to ensure a homogenous environment with respect to process parameters such as pH, dissolved oxygen tension (DOT) and temperature, maintaining a well mixed cell suspension and blending nutrient feeds within the bioreactor.
  • This provides the necessary physicochemical environment for optimal cell growth, product accumulation and product quality.
  • Key to the design philosophy is the need to maintain geometric similarity. This allows a scale down model to be developed at 12 litre laboratory and 500 litre pilot scales.
  • the design of the seed and production bioreactors are based on the same principles although some departures are required to allow for flexibility in processing.
  • the aspect ratios (H L /T) selected are typical of those used in mammalian cell culture and are in the range 0.17 to 1.96 post-inoculation.
  • the design constraint is based upon a seeding ratio of 11% v/v (1 in 9 dilution) and 20% v/v (1 in 5 dilution), with feed application of 4% v/v to 25% v/v of the post-inoculation volume.
  • the post-inoculation volume in the production bioreactor is adjusted for feed applications up to 15% such that after the addition of all the feeds the final volume at harvest ends up at 20 000 l. However for feed applications greater then 15% v/v the post-inoculation volume is adjusted for a 15% v/v feed but following the application of feeds the final pre-harvest volume will be a minimum of 20 000 and a maximum 22 000 litres.
  • the production bioreactor is expected to hold a total of 20 000 to 22 000 litres at the end of a batch.
  • Table 26 shows the pre-inoculation volume, inoculation volume and transfer or harvest volume for each of the three inoculum expansion stages and the production bioreactor.
  • the seed bioreactors (stage N-1 to N-3) are unlikely to be fed therefore the maximum operating volume will be at inoculation.
  • the operating volume range for the 4000 litre seed bioreactor (stage N-1) is 1914 to 3846 litres.
  • the 1000 litre seed bioreactor (stages N-2 and N-3) will operate at two operating ranges.
  • the bioreactor train can produce sufficient culture to meet forward processing cell concentration criteria in a single expansion/sub-cultivation stage.
  • the bioreactor train requires two expansion/sub-cultivation stages to meet forward processing criteria for 20% v/v seed split ratio process.
  • an operating range of 400 to 450 litres is required and for the 20% v/v seed split ratio process an operating volume range of 250 to 960 litres is required.
  • the 1000 litre seed bioreactor is inoculated from culture produced in an S200 Wave bioreactor.
  • This bioreactor is operated in batches of up to 5 days, with potential “shot additions” of feeds, for cultivation of mammalian cells. However due to repeated drain and refill operation at the end of each batch the total process residence time in this bioreactor can exceed 30 days.
  • the mammalian cells are kept in a homogeneous suspension by agitation via an identical impeller system to the 20 000 litre bioreactor. Additionally other features will be kept geometrically similar to the 20 000 litre bioreactor, where possible.
  • Sparging air or oxygen and air or nitrogen respectively will control process DOT.
  • Process pH is controlled by addition of alkali for base control and of sparged CO 2 for acid control.
  • the process operating volume of the bioreactor changes at different phases of operation. Initially the bioreactor is aseptically filled with a bolus of medium at 250 to 400 litres in 0.5 h. The bioreactor is operated in a pre-inoculation phase to bring the process variables to predefined set points. 50 litre culture from a (N-4) S-200 seed wave bioreactor is inoculated, by pneumatic assisted flow, or pumped with a peristaltic pump in 25 to 30 minutes into the 1000 litre bioreactor at 1 in 5 or 1 in 9 dilutions. The post-inoculation operating volume is 300 and 450 litres for 1 in 5 and 1 in 9 seeded process respectively.
  • the addition of alkali for base control and 1 in 10 antifoam suspension for suppression of foam contributes towards the final volume.
  • the inoculum culture may be fed by a “shot addition” if the culture interval is longer then expected.
  • shots addition if the culture interval is longer then expected.
  • the N-3 stage ends when viable cell concentration reaches transfer criteria.
  • the N-2 stage for 1 in 5 process begins with a bulk up in volume to 960 litre by draining of 192 litre excess culture and addition of 768 litre fresh medium in 1.5 h. 696 to 769 litre of culture are transferred at the end of N-2 stage to the 4000 litre bioreactor for the 1 in 5 processes. For the 1 in 9 processes 239 litres are transferred to the 4000 litre bioreactor.
  • the 1000 l bioreactor is continuously “drained and refilled with fresh medium” or “rolled” to provide back up culture for the 4000 litre bioreactor.
  • the duration of the rolling seed operation is dependent on the length of the production campaign and the permissible elapsed generations number of the seed culture. Typically it is assumed that rolling seed operation is in excess of 30 days.
  • the rolling operation consists of retaining approximately 192 litres of the 960 litre culture and diluting with 768 litre fresh medium for the 1 in 5 processes.
  • the 1000 litre bioreactor is expected to be “rolled” by retaining 50 to 100 litre of the 450 to 900 litre culture and diluting with 400 to 800 litre fresh medium. Process control ranges are relaxed over this operation.
  • the medium added to the bioreactor during rolling operation is warmed to 30° C.
  • This bioreactor is operated in batch of no more then 5 days, with potential “shot additions” of feeds, for cultivation of mammalian cells.
  • the mammalian cells are kept in a homogeneous suspension by agitation via an identical impeller system described in example 1. Additionally this vessel is geometrically similar to the 20 000 litre bioreactor.
  • Process pH is controlled by addition of alkali for base control and of sparged CO 2 for acid control.
  • the process operating volume of the bioreactor changes at different phases of operation. Initially the bioreactor is aseptically filled with a bolus of protein free medium at 1914 to 3077 litres in 1.5 h. The bioreactor operates in a pre-inoculation phase to bring the process variables to predefined set points. Culture from the 1000 litre (N-2) seed seed bioreactor is inoculated by pneumatic flow at a flowrate to allow transfer in one hour, at 1 in 5 or 1 in 9 dilutions. The post-inoculation operating volume is 2153 to 3846 litres. The addition of alkali for base control and 1 in 10 antifoam suspension for suppression of foam contributes towards the final volume.
  • the inoculum culture may be fed by a “shot addition” if the culture interval is longer then expected. As a result of mixing and gassing the liquid volume expands due to gas hold up. The extent of this rise is dependent on the sparger type used, power per unit volume imparted by impellers and superficial gas velocity of sparged gasses.
  • This bioreactor is operated in batch or fed batch mode for 10 to 15 days for the cultivation of mammalian cells.
  • the mammalian cells are kept in a homogeneous suspension by agitation via an impeller system.
  • the process operating volume of the bioreactor changes at different phases of operation. Initially the bioreactor is aseptically filled with cell culture medium at 13913 to 17096 litres in 1-2 h. The bioreactor is operated in a pre-inoculation phase to bring the process variables to predefined set points. Culture from the 4000 litre seed bioreactor (N-1) is inoculated by pneumatic flow at a flow rate range of ⁇ 4000 l/h into the 20 000 litre bioreactor at 1 in 5 or 1 in 9 dilutions. The post-inoculation volume continuously increases following an application of sub-surface feeds to maximum of 20 000 litres (two feeds totaling 4 to 25% v/v).
  • alkali for base control and 1 in 10 antifoam suspension for suppression of foam accounts for about 100 litres and 20 litres respectively.
  • the liquid volume expands due to gas hold up.
  • the extent of this rise is depended on the sparger type used (fluted or sintered), power per unit volume imparted by impellers and superficial gas velocity of sparged gasses.
  • Table 27 describes the aspect ratios in the 20 000 litre bioreactor at various operating volumes during normal processing. The aspect ratios have been tested at 500 litre scale and provided the superficial gas velocity and power per unit volume are kept constant the K L a remains constant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Sustainable Development (AREA)
  • Cell Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US13/148,503 2009-02-09 2010-02-09 Bioreactor for the cultivation of mammalian cells Abandoned US20110312087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09001755.9 2009-02-09
EP09001755A EP2216395A1 (fr) 2009-02-09 2009-02-09 Bioréacteur pour la culture de cellules de mammifères
PCT/EP2010/000783 WO2010089151A1 (fr) 2009-02-09 2010-02-09 Bioréacteur pour la culture de cellules de mammifère

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/000783 A-371-Of-International WO2010089151A1 (fr) 2009-02-09 2010-02-09 Bioréacteur pour la culture de cellules de mammifère

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/885,802 Division US9670446B2 (en) 2009-02-09 2015-10-16 Bioreactor for the cultivation of mammalian cells
US14/885,827 Continuation US9783771B2 (en) 2009-02-09 2015-10-16 Three bioreactor system for the cultivation of mammalian cells

Publications (1)

Publication Number Publication Date
US20110312087A1 true US20110312087A1 (en) 2011-12-22

Family

ID=40848586

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/148,503 Abandoned US20110312087A1 (en) 2009-02-09 2010-02-09 Bioreactor for the cultivation of mammalian cells
US14/885,802 Active US9670446B2 (en) 2009-02-09 2015-10-16 Bioreactor for the cultivation of mammalian cells
US14/885,827 Active 2030-08-14 US9783771B2 (en) 2009-02-09 2015-10-16 Three bioreactor system for the cultivation of mammalian cells
US15/612,769 Active US10179898B2 (en) 2009-02-09 2017-06-02 Bioreactor for the cultivation of mammalian cells
US16/189,529 Active US10883076B2 (en) 2009-02-09 2018-11-13 Bioreactor for the cultivation of mammalian cells

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/885,802 Active US9670446B2 (en) 2009-02-09 2015-10-16 Bioreactor for the cultivation of mammalian cells
US14/885,827 Active 2030-08-14 US9783771B2 (en) 2009-02-09 2015-10-16 Three bioreactor system for the cultivation of mammalian cells
US15/612,769 Active US10179898B2 (en) 2009-02-09 2017-06-02 Bioreactor for the cultivation of mammalian cells
US16/189,529 Active US10883076B2 (en) 2009-02-09 2018-11-13 Bioreactor for the cultivation of mammalian cells

Country Status (15)

Country Link
US (5) US20110312087A1 (fr)
EP (3) EP2216395A1 (fr)
JP (2) JP2012517217A (fr)
KR (1) KR20110137302A (fr)
CN (2) CN104726334A (fr)
AU (1) AU2010211239A1 (fr)
BR (1) BRPI1008219A2 (fr)
CA (1) CA2749185A1 (fr)
CL (1) CL2011001926A1 (fr)
EA (1) EA201171018A1 (fr)
ES (1) ES2860499T3 (fr)
IL (1) IL214529A0 (fr)
NZ (1) NZ594049A (fr)
WO (1) WO2010089151A1 (fr)
ZA (1) ZA201104931B (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD664262S1 (en) * 2010-09-24 2012-07-24 Lonza Ag Impeller arrangement for fermenter
USD681690S1 (en) * 2012-02-20 2013-05-07 Outotec Oyj Mixer impeller
US9447378B2 (en) 2012-04-27 2016-09-20 Massachusetts Institute Of Technology Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes
US9816070B2 (en) 2013-06-14 2017-11-14 Massachusetts Institute Of Technology Articles and methods for stem cell differentiation
WO2017207822A1 (fr) 2016-06-03 2017-12-07 Lonza Limited Bioréacteur à usage unique
WO2017212071A1 (fr) 2016-06-10 2017-12-14 Lonza Ltd Procédé de stabilisation de protéines
US20180010082A1 (en) * 2016-06-03 2018-01-11 Lonza Ltd Bioreactor With Higher Agitation Rates
WO2018026956A1 (fr) 2016-08-02 2018-02-08 Lonza Ltd Procédé et système permettant de fournir des solutions tampon
US10023831B2 (en) 2014-03-17 2018-07-17 Biogen Ma Inc. Gas delivery devices and associated systems and methods
CN108410734A (zh) * 2018-05-17 2018-08-17 江苏弗洛瑞生物工程设备有限公司 一种细胞培养生物反应器
US10139418B2 (en) 2010-10-27 2018-11-27 Lonza Biologics Plc Rapid method for targeted cell (line) selection
US10179901B2 (en) 2009-07-09 2019-01-15 Massachusetts Institute Of Technology Methods and compositions for increased safety of stem cell-derived populations
CN109312291A (zh) * 2016-06-24 2019-02-05 隆萨有限公司 可变直径生物反应器
WO2020014618A1 (fr) 2018-07-13 2020-01-16 Lonza Ltd Procédés d'amélioration de la production de produits biologiques par réduction du taux de protéine endogène
US10723990B2 (en) 2013-04-19 2020-07-28 Emd Millipore Corporation Flexible film in single use bioreactor
US20210002601A1 (en) * 2014-10-24 2021-01-07 Genzyme Corporation Integrated Continuous Isolation of Fluid Streams From Sterile Process Vessels
US20210147781A1 (en) * 2018-06-27 2021-05-20 Fujifilm Corporation Cell culture method, product producing method, and cell culture device
CN113286650A (zh) * 2018-09-06 2021-08-20 动量制药公司 连续细胞培养方法
US11584910B2 (en) * 2018-01-17 2023-02-21 Life Technologies Corporation System and method for cell culture scaling
EP4324905A1 (fr) * 2022-08-19 2024-02-21 Sartorius Stedim Biotech GmbH Système de bioréacteur avec installation de fumigation
US12077742B2 (en) 2015-12-29 2024-09-03 Life Technologies Corporation Methods for fluid mixing systems with laterally displaced flexible drive lines
US12128371B2 (en) 2012-04-06 2024-10-29 Life Technologies Corporation Fluid mixing system with flexible drive line and foldable impeller

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2216395A1 (fr) 2009-02-09 2010-08-11 Lonza Biologics plc. Bioréacteur pour la culture de cellules de mammifères
US9969965B2 (en) 2011-01-11 2018-05-15 Ge Healthcare Bio-Sciences Corp. Linearly scalable single use bioreactor system
JP6178786B2 (ja) * 2011-05-13 2017-08-09 オクタファルマ・アーゲー 組換えｆｖｉｉｉの生産において真核細胞の生産性を向上させる方法
EP2864029B1 (fr) * 2012-06-26 2020-02-19 GE Healthcare Bio-Sciences AB Sac pliable à dispositif anti-tourbillon souple
JP5942830B2 (ja) * 2012-12-11 2016-06-29 住友金属鉱山株式会社 撹拌反応装置
FR3004724B1 (fr) * 2013-04-22 2015-05-22 Fermentalg Reacteur a eclairage integre
EP3046644A4 (fr) * 2013-09-16 2017-08-09 F. Hoffmann-La Roche AG Bioréacteurs dotés de modèles d'agitateurs multiples ou à position réglable
KR101656930B1 (ko) * 2014-07-02 2016-09-12 주식회사 엘지화학 교반탱크 반응기 및 이를 이용한 pvc 수지의 제조방법
JP6764221B2 (ja) * 2015-07-22 2020-09-30 株式会社日立製作所 攪拌装置
CN105123270A (zh) * 2015-08-31 2015-12-09 佛山市高明区更合镇鹏鹄食用菌专业合作社 一种椴木灵芝的种植方法
US11719704B2 (en) 2015-12-30 2023-08-08 Momenta Pharmaceuticals, Inc. Methods related to biologics
US10323223B2 (en) * 2016-01-22 2019-06-18 Pbs Biotech, Inc. Homogeneous cell dispensing mixer
CN105602901B (zh) * 2016-03-11 2020-01-31 广州赛莱拉干细胞科技股份有限公司 生物反应器及其搅拌桨和使用其培养til细胞的方法
ES2985769T3 (es) * 2017-05-06 2024-11-07 Upside Foods Inc Composiciones y métodos para aumentar la densidad de cultivo de una biomasa celular dentro de una infraestructura de cultivo
HUE058668T2 (hu) 2017-06-30 2022-09-28 Inscripta Inc Automatizált sejtkezelési eljárások, modulok, berendezések és rendszerek
US11609120B2 (en) 2017-10-06 2023-03-21 Lonza Ltd Automated control of cell culture using Raman spectroscopy
WO2019126654A1 (fr) * 2017-12-22 2019-06-27 Cuello Joel L Bioréacteur à dispersion axiale (adbr) pour la production de microalgues et autres micro-organismes
CN112262250A (zh) 2018-03-09 2021-01-22 斯伦贝谢技术有限公司 集成井施工系统操作
KR102444162B1 (ko) * 2018-04-10 2022-09-19 이엠디 밀리포어 코포레이션 채널을 갖는 접을 수 있는 배플을 포함하는 단일 사용 용기
WO2020028616A1 (fr) 2018-08-02 2020-02-06 Lonza Ltd Procédés de fabrication d'une protéine de recombinaison comprenant une liaison disulfure
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
IL316267A (en) * 2018-10-03 2024-12-01 Pluri Biotech Ltd Modular bioreactor
CA3125443A1 (fr) 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Procedes de production d'ustekinumab
USD894377S1 (en) 2019-01-03 2020-08-25 Life Technologies Corporation Tube management assembly
EP3924097A4 (fr) * 2019-02-11 2022-11-16 Culture Biosciences, Inc. Récipient de bioréacteur pour système de fermentation automatisé
US11739289B2 (en) 2019-04-22 2023-08-29 Lonza Ltd Continuous blade impeller
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
US11535421B2 (en) * 2019-12-30 2022-12-27 Global Life Sciences Solutions Usa Llc System and method for packaging a bioprocessing bag and associated components, and packaging for a bioprocessing bag
US12055027B2 (en) 2020-03-06 2024-08-06 Schlumberger Technology Corporation Automating well construction operations based on detected abnormal events
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
CN111549002B (zh) * 2020-06-01 2021-03-02 哈尔滨元亨生物药业有限公司 一种利用高密度培养方式生产犬细小病毒单克隆抗体的方法
EP4256025A1 (fr) * 2020-12-04 2023-10-11 Sciperio, Inc. Bioréacteur à volume à expansion continue
RU2763318C1 (ru) * 2021-01-12 2021-12-28 Общество С Ограниченной Ответственностью "Центр Вихревых Технологий" Лабораторный мультиплатформенный газовихревой биореактор
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
CN113477205A (zh) * 2021-07-14 2021-10-08 南京延长反应技术研究院有限公司 一种气液自动混合系统及其方法
CN113846013B (zh) * 2021-11-30 2022-03-22 威海银河生物技术有限公司 一种药用海藻酸钠生产用酶解罐
US11884909B2 (en) * 2022-04-25 2024-01-30 Ark Biotech Inc. Cluster airlift bioreactor
KR20250030442A (ko) * 2022-05-06 2025-03-05 아벡, 아이엔씨. 생물반응기 시스템
EP4531918A2 (fr) * 2022-06-01 2025-04-09 TG Therapeutics Inc. Production de protéines recombinantes à l'échelle commerciale dans des cellules d'hybridomes de rat
EP4400206A1 (fr) 2023-01-16 2024-07-17 Universidad de Sevilla Réservoir agité à distribution de bulles à homogénéité améliorée et procédé associé
WO2025029135A1 (fr) * 2023-08-01 2025-02-06 Central Corporate Engineering Sdn Bhd Dispositif de culture pour la culture d'euglena
US20250122463A1 (en) * 2023-10-11 2025-04-17 Caladan Bio Inc Bioreactor for non-contact sensing

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378436A (en) * 1979-09-08 1983-03-29 Hoechst Aktiengesellschaft Process and device for improving the quality of mixing of liquid especially viscous media
US5882913A (en) * 1997-08-07 1999-03-16 The United States Of American As Represented By The Secretary Of Agriculture Strain of gypsy moth virus with enhanced polyhedra and budded virus production
US5888806A (en) * 1997-01-10 1999-03-30 Nguyen; Quang A. Tower reactors for bioconversion of lignocellulosic material
US20010055237A1 (en) * 1998-09-28 2001-12-27 Kubera Paul M. Mixer systems
US20050239199A1 (en) * 2004-04-27 2005-10-27 Baxter International Inc. Stirred-tank reactor system
US20080068920A1 (en) * 2006-06-16 2008-03-20 Xcellerex, Inc. Gas delivery configurations, foam control systems, and bag molding methods and articles for collapsible bag vessels and bioreactors
US20090035856A1 (en) * 2007-07-30 2009-02-05 Xcellerex, Inc. Continuous perfusion bioreactor system
US20090208390A1 (en) * 2006-05-10 2009-08-20 Lucite International Uk Limited Mixing apparatus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584269A (en) * 1983-10-31 1986-04-22 Genex Corporation Method for stabilizing the enzymatic activity of phenylalanine ammonia lyase during L-phenylalanine production
US5075234A (en) * 1988-11-02 1991-12-24 Josefino Tunac Fermentor/bioreactor systems having high aeration capacity
US5356600A (en) * 1990-09-24 1994-10-18 Praxair Technology, Inc. Oxygen enrichment method and system
US5342763A (en) * 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
EP0698662B1 (fr) * 1994-07-26 2001-06-06 Shin-Etsu Chemical Co., Ltd. Appareil et méthode pour la production de gomme de xanthane
WO2004025125A2 (fr) 1998-09-28 2004-03-25 The Penn State Research Foundation Rotors d'aeration de surface
GB9905646D0 (en) * 1999-03-11 1999-05-05 Cobra Therapeutics Ltd A vessel for mixing a cell lysate
MXPA01009095A (es) * 1999-03-12 2003-07-14 Shinko Pantec Co Ltd Tanque agitado para almacenar mezcla de levadura, metodo para fabricar alimentos fermentados tales como cerveza utilizando el tanque agitado y un propulsor de agitacion provisto en el tanque agitado.
KR20010078021A (ko) 2000-01-24 2001-08-20 조안 엠. 젤사 ; 로버트 지. 호헨스타인 ; 도로시 엠. 보어 헤드스페이스 기체를 재수용하기 위한 방법
JP4279669B2 (ja) 2001-08-31 2009-06-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト 高細胞密度発酵を実施するためのユニットおよび方法
US7201884B2 (en) * 2001-12-26 2007-04-10 E. I. Du Pont De Nemours And Company Process and apparatus for performing a gas-sparged reaction
JP4260425B2 (ja) 2002-06-04 2009-04-30 花王株式会社 液体洗浄剤組成物
JP2006503687A (ja) * 2002-09-16 2006-02-02 ザ ペン ステイト リサーチ ファンデーション 表面曝気羽根車
US20060223155A1 (en) * 2002-11-01 2006-10-05 Jackson Streeter Enhancement of in vitro culture or vaccine production in bioreactors using electromagnetic energy
CN1232631C (zh) * 2004-03-04 2005-12-21 江南大学 一种耦合式生物反应器
GB0410118D0 (en) * 2004-05-06 2004-06-09 Glaxo Group Ltd Novel bioreactor
KR20070122197A (ko) * 2005-03-22 2007-12-28 산토리 가부시키가이샤 통기 교반형 배양조
US7718405B2 (en) * 2005-09-19 2010-05-18 American Air Liquide, Inc. Use of pure oxygen in viscous fermentation processes
JP4475280B2 (ja) * 2007-01-26 2010-06-09 株式会社日立プラントテクノロジー 細胞培養方法及び細胞培養装置
JP2009072133A (ja) * 2007-09-21 2009-04-09 Hitachi Plant Technologies Ltd 培養槽装置、細胞培養方法及び物質生産方法
EP2216395A1 (fr) * 2009-02-09 2010-08-11 Lonza Biologics plc. Bioréacteur pour la culture de cellules de mammifères

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378436A (en) * 1979-09-08 1983-03-29 Hoechst Aktiengesellschaft Process and device for improving the quality of mixing of liquid especially viscous media
US5888806A (en) * 1997-01-10 1999-03-30 Nguyen; Quang A. Tower reactors for bioconversion of lignocellulosic material
US5882913A (en) * 1997-08-07 1999-03-16 The United States Of American As Represented By The Secretary Of Agriculture Strain of gypsy moth virus with enhanced polyhedra and budded virus production
US20010055237A1 (en) * 1998-09-28 2001-12-27 Kubera Paul M. Mixer systems
US20050239199A1 (en) * 2004-04-27 2005-10-27 Baxter International Inc. Stirred-tank reactor system
US20090208390A1 (en) * 2006-05-10 2009-08-20 Lucite International Uk Limited Mixing apparatus
US20080068920A1 (en) * 2006-06-16 2008-03-20 Xcellerex, Inc. Gas delivery configurations, foam control systems, and bag molding methods and articles for collapsible bag vessels and bioreactors
US20090035856A1 (en) * 2007-07-30 2009-02-05 Xcellerex, Inc. Continuous perfusion bioreactor system

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179901B2 (en) 2009-07-09 2019-01-15 Massachusetts Institute Of Technology Methods and compositions for increased safety of stem cell-derived populations
USD664262S1 (en) * 2010-09-24 2012-07-24 Lonza Ag Impeller arrangement for fermenter
US10139418B2 (en) 2010-10-27 2018-11-27 Lonza Biologics Plc Rapid method for targeted cell (line) selection
USD681690S1 (en) * 2012-02-20 2013-05-07 Outotec Oyj Mixer impeller
US12128371B2 (en) 2012-04-06 2024-10-29 Life Technologies Corporation Fluid mixing system with flexible drive line and foldable impeller
US12226743B2 (en) 2012-04-06 2025-02-18 Life Technologies Corporation Methods for mixing a fluid with foldable impellers
US9447378B2 (en) 2012-04-27 2016-09-20 Massachusetts Institute Of Technology Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes
US10723990B2 (en) 2013-04-19 2020-07-28 Emd Millipore Corporation Flexible film in single use bioreactor
US9816070B2 (en) 2013-06-14 2017-11-14 Massachusetts Institute Of Technology Articles and methods for stem cell differentiation
US10023831B2 (en) 2014-03-17 2018-07-17 Biogen Ma Inc. Gas delivery devices and associated systems and methods
US20210002601A1 (en) * 2014-10-24 2021-01-07 Genzyme Corporation Integrated Continuous Isolation of Fluid Streams From Sterile Process Vessels
US12077742B2 (en) 2015-12-29 2024-09-03 Life Technologies Corporation Methods for fluid mixing systems with laterally displaced flexible drive lines
US10801003B2 (en) * 2016-06-03 2020-10-13 Lonza Ltd Single use bioreactor
US20180010082A1 (en) * 2016-06-03 2018-01-11 Lonza Ltd Bioreactor With Higher Agitation Rates
US20170349874A1 (en) * 2016-06-03 2017-12-07 Lonza Ltd Single Use Bioreactor
WO2017207822A1 (fr) 2016-06-03 2017-12-07 Lonza Limited Bioréacteur à usage unique
US11371002B2 (en) * 2016-06-03 2022-06-28 Lonza Ltd Single use bioreactor
WO2017212071A1 (fr) 2016-06-10 2017-12-14 Lonza Ltd Procédé de stabilisation de protéines
US10975409B2 (en) 2016-06-10 2021-04-13 Lonza Ltd Method for stabilizing proteins
US11993802B2 (en) 2016-06-10 2024-05-28 Lonza Ltd Method for stabilizing proteins
CN109312291A (zh) * 2016-06-24 2019-02-05 隆萨有限公司 可变直径生物反应器
US10370629B2 (en) * 2016-06-24 2019-08-06 Lonza Limited Variable diameter bioreactors
US12227723B2 (en) 2016-06-24 2025-02-18 Lonza Ltd Variable diameter bioreactors
EP3475410A4 (fr) * 2016-06-24 2020-02-12 Lonza Ltd Bioréacteurs à diamètre variable
US11597900B2 (en) 2016-06-24 2023-03-07 Lonza Ltd. Variable diameter bioreactors
WO2018026956A1 (fr) 2016-08-02 2018-02-08 Lonza Ltd Procédé et système permettant de fournir des solutions tampon
US11584910B2 (en) * 2018-01-17 2023-02-21 Life Technologies Corporation System and method for cell culture scaling
US12227732B2 (en) 2018-01-17 2025-02-18 Life Technologies Corporation Systems for cell culture scaling
CN108410734A (zh) * 2018-05-17 2018-08-17 江苏弗洛瑞生物工程设备有限公司 一种细胞培养生物反应器
US20210147781A1 (en) * 2018-06-27 2021-05-20 Fujifilm Corporation Cell culture method, product producing method, and cell culture device
WO2020014618A1 (fr) 2018-07-13 2020-01-16 Lonza Ltd Procédés d'amélioration de la production de produits biologiques par réduction du taux de protéine endogène
CN113286650A (zh) * 2018-09-06 2021-08-20 动量制药公司 连续细胞培养方法
EP4324905A1 (fr) * 2022-08-19 2024-02-21 Sartorius Stedim Biotech GmbH Système de bioréacteur avec installation de fumigation
WO2024037823A1 (fr) * 2022-08-19 2024-02-22 Sartorius Stedim Biotech Gmbh Système de bioréacteur avec installation d'alimentation en gaz

Also Published As

Publication number Publication date
EP3540040B1 (fr) 2021-01-13
AU2010211239A1 (en) 2011-08-04
US20160032232A1 (en) 2016-02-04
CN102307984A (zh) 2012-01-04
WO2010089151A8 (fr) 2010-11-18
US9670446B2 (en) 2017-06-06
BRPI1008219A2 (pt) 2015-08-25
US20190078045A1 (en) 2019-03-14
CL2011001926A1 (es) 2012-01-06
ES2860499T3 (es) 2021-10-05
ZA201104931B (en) 2012-09-26
EP2393912B1 (fr) 2020-04-29
JP6121374B2 (ja) 2017-04-26
US10883076B2 (en) 2021-01-05
US20170267962A1 (en) 2017-09-21
US20160040110A1 (en) 2016-02-11
JP2012517217A (ja) 2012-08-02
EP2216395A1 (fr) 2010-08-11
EA201171018A1 (ru) 2012-03-30
NZ594049A (en) 2012-02-24
US9783771B2 (en) 2017-10-10
EP2393912B9 (fr) 2020-09-23
WO2010089151A1 (fr) 2010-08-12
IL214529A0 (en) 2011-09-27
US10179898B2 (en) 2019-01-15
EP2393912A1 (fr) 2011-12-14
KR20110137302A (ko) 2011-12-22
CN104726334A (zh) 2015-06-24
JP2015043776A (ja) 2015-03-12
EP3540040A1 (fr) 2019-09-18
CA2749185A1 (fr) 2010-08-12

Similar Documents

Publication Publication Date Title
US10883076B2 (en) Bioreactor for the cultivation of mammalian cells
Chisti Pneumatically agitated bioreactors in industrial and environmental bioprocessing: hydrodynamics, hydraulics, and transport phenomena
EP2039754B1 (fr) Bioréacteur, procédé de culture cellulaire, et procédé de production de substance
Marks Equipment design considerations for large scale cell culture
JP4845737B2 (ja) 細胞培養システム
US20070172945A1 (en) Bioreactor
JP2021511033A (ja) 細胞培養規模拡縮のためのシステムおよび方法
KR20070015178A (ko) 교반-탱크 반응기 시스템
Chandrashekhar et al. An overview of fermenter and the design considerations to enhance its productivity
Galliher et al. Single‐use bioreactor platform for microbial fermentation
Kreitmayer et al. Numerical and experimental characterization of the single-use bioreactor Xcellerex™ XDR-200
US20120295248A1 (en) Systems and methods for dynamic gas control in a disposable vessel
RU2741346C1 (ru) Устройство для выращивания микроорганизмов
Regonesi Bioreactors: A Complete Review
EP3592835B1 (fr) Systèmes et méthodes de fermentation aérobie
DeWilde et al. Bridging the gap from reusable to single-use manufacturing with stirred, single-use bioreactors
WO2022154690A1 (fr) Bioréacteur à tourbillons de gaz à plateformes multiples de laboratoire
HK1160162A (en) Bioreactor for the cultivation of mammalian cells
Tonso et al. Agitation and Aeration: Oxygen Transfer and Cell Respiration
WO2024191572A1 (fr) Système de boréacteurs à évolution linéaire
JPS59183687A (ja) 栄養源溶液中における微生物の培養方法及び装置

Legal Events

Date Code Title Description
AS Assignment

Owner name: LONZA BIOLOGICS PLC, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KHAN, MOHSAN;REEL/FRAME:026792/0519

Effective date: 20110729

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION